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Dr. Joan Brugge        Alice S. Kaanta 
Evidence for a novel multipotent mammary progenitor with pregnancy-
specific activity 
Abstract 
 The mouse mammary gland has emerged as a model system for studying processes 
involved in the development of epithelial tissues.  Current evidence suggests the existence of 
a differentiation hierarchy in the mammary gland, consisting of a stem cell capable of 
reconstituting the tissue, progenitors with the capacity to produce specific functional cell 
types, and differentiated cells with limited or no repopulation potential.  Although markers 
for mammary stem cells and progenitors have been identified, these populations have not 
been isolated to purity and our understanding of how they function in different stages of 
mammary development remains incomplete.   
 Many adult stem cells are mitotically quiescent and can therefore retain a DNA or 
histone label significantly longer than differentiated cells.  In an attempt to identify 
mammary stem cells/progenitors by histone label retention, I crossed a mouse carrying the 
tetracycline-inducible histone 2b/eGFP (H2BGFP) gene with tetracycline transactivator 
strains expected to induce H2BGFP in the mammary gland.  H2BGFP expression was 
induced in the mammary gland until puberty and then chased for 6-8 weeks; H2BGFP+ label 
retaining cells were isolated and assayed.  Transplantation experiments comparing 
MMTVrtTA/H2BGFP MECs isolated after induction to MMTVrtTA/H2BGFP MECs 
retaining label post-chase failed to prove that label retention enriches for stem 
cells/progenitors in the MMTVrtTA/H2BGFP system.  During the course of these 
experiments, I unexpectedly discovered that MMTVrtTA induced H2BGFP expression 
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exclusively in the CD24+/CD29+ and CD24+/CD29lo populations, which contain stem cells 
and progenitors, respectively.   
 Interestingly, I also discovered that H2BGFP+/CD24+/CD29lo MECs developed 
limited mammary outgrowths in vivo and that pregnancy increased the repopulation ability of 
these cells by 5-10-fold.  H2BGFP+/CD24+/CD29lo outgrowths contained all mammary 
lineages and produced milk, but were unable to self-renew in serial transplant assays.  
Furthermore, H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo MECs had distinct 
gene expression profiles, with H2BGFP+/CD24+/CD29lo MECs expressing lower levels 
of transcripts involved in mammary development and differentiation.   
 These data provide evidence for the existence of a multipotent, pregnancy-activated 
mammary progenitor and suggests that different progenitor populations are responsible for 
mammary expansion during puberty and pregnancy.  Future studies may identify FACS 
markers for purification of pregnancy-activated progenitors and further elucidate the role of 
different mammary cell types during pregnancy.   
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Chapter 1 Introduction  
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Overview of Mammary Development in the Mouse  
The mammary gland is an impressively dynamic epithelial tissue.  During the lifetime 
of a female mammal, the mammary gland undergoes three distinct modes of growth: the 
pubertal ductal elongation and branching which establishes the mammary architecture, the 
cyclic expansion and regression of the estrus/menstrual cycle, and the dramatic pregnancy-
associated proliferation and alveolar differentiation that is critical for lactation [6].  These 
processes are governed by different signals and hormones, and could involve the activity of 
different cell types at each stage [7, 8].   
The adult mammary gland is a branched network of bilayer ducts.  Each duct is 
composed of an inner luminal layer and an outer myoepithelial layer (Figure 1-1, top) [1].  
Luminal cells are cuboidal in shape and are often identified by expression of cytokeratin 8 
(CK8) and cytokeratin 18 (CK18) [9].  The myoepithelium comprises a continuous layer of 
long, thin cells, which express cytokeratin 14 (CK14), p63 and smooth muscle actin (SMA).  
Contractile force from the myoepithelial layer is required for the movement of milk from 
alveoli, through the ducts and towards the nipple during lacation [10].  Spaced at intervals in 
the myoepithelial layer are basal cells, small rounded cells that express CK14 and the 
transcription factor p63 [11].  By flow cytometric analysis, p63+ cells are found in mammary 
epithelial cell (MEC) sub-populations with stem cell activity [7, 12, 13].  
The mouse mammary gland is first detectable as an epithelial placode during 
embryogenesis at E11.  This placode develops into a small bud between E13-E15 and 
eventually becomes a small branched structure with short ducts by E18 [14].  At the onset of 
puberty (approximately three weeks of age, for the female mouse) estrogen signaling initiates 
the development of the mammary gland [15]. A club-shaped, multi-layer structure known as 
the terminal end bud (TEB) develops at the tip of each mammary duct (Figure 1-1, bottom).  
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TEBs  are the major site of mammary proliferation during puberty and comprise an outer 
layer of cap cells and an inner mass of body cells.  CK14 expression begins at the neck of the 
TEB where the outer cap cells cease proliferation and differentiate into myoepithelial cells.  .  
Most TEB body cells express CK8, with a small number of CK14+ and p63+ cells 
interspersed throughout.  Cap cells are p63+, but have a cuboidal shape and are larger than 
most basal cells[16].  Within TEBs, rapid proliferation combined with Bcl-2/Bim-mediated 
apoptosis results in a hollow bilayer ductal structure [17].  Throughout puberty, TEBs 
bifurcate at intervals, generating new branches of the mammary duct.  Once the mammary 
network has reaches the outer perimeter of the mammary fat pad, ductal elongation ceases 
and TEBs regress, forming distal end tips.   
Figure 1-1. Schematic of the Mouse Mammary Gland. Cross section of a mouse mammary duct (top). Longitudinal 
section of a terminal end bud (bottom).  From Visvader et al. [1] 
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Upon reaching sexual maturity, the female mouse begins four- to six- day estrous 
cycles, during which the mammary gland undergoes a cyclical process of expansion and 
regression (Figure 1-2).  Whereas pubertal mammary expansion is primarily a process of 
ductal elongation, with some branching to generate new ducts, the estrous cycle produces 
small side branches, presumably as a prelude to alveologenesis during pregnancy.  The four 
stages of the estrus cycle, proestrus, estrus, metestrus and diestrus are characterized by 
different levels of estrogen and progesterone [18].  During proestrus, estrogen levels rise and 
progesterone levels fall, in preparation for ovulation.  At estrus, estrogen levels have reached 
their peak, progesterone levels are at their nadir, and the female mouse ovulates.  Estrus is 
followed by metestrus, during which estrogen levels fall and progesterone levels rise.  It is 
during diestrus, the longest phase of the estrous cycle, that the appearance of pre-alveolar 
structures and side branches in the mammary gland is most prominent; later in diestrus, 
Figure 1-2. Whole Mounts of the Mouse Mammary Gland during the Estrous Cycle. Mammary gland whole mounts 
during a) proestrus b) estrus c) metestrus d) diestrus.  From Joshi et al. [2] 
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many of these side branches and alveolar growths undergo apoptosis, restoring the 
mammary gland to its original state for the next cycle [6, 18]. 
If the female is fertilized during estrus, rising progesterone levels during early 
pregnancy initiate the development of small side branches throughout the mammary gland 
[19] (Figure 1-3).   Instead of undergoing apoptosis, as occurs in estrus, these side branches 
become the structural scaffold for developing alveoli [3].  Prolactin signaling induces the 
growth of rounded structures, known as alveolar buds, at the distal ends of these side 
branches.  During mid-pregnancy, alveolar buds divide into numerous individual alveoli, 
forming alveolar clusters, which expand rapidly, filling the mammary fat pad [20].  Unlike 
pubertal proliferation, which produces a contiguous myoepithelium on the outside of the 
luminal cell layer, alveologenesis results in an expanded, but non-continuous, myoepithelial 
layer, such that luminal cells are in direct contact with the extracellular matrix [21].  At 
approximately day 18 of pregnancy, secretory cells within the alveoli begin to produce milk.  
Females give birth around day 20 of pregnancy, after a drop in progesterone levels and the 
Figure 1-3. Whole Mounts of the Mammary Gland during Pregnancy. Mammary gland whole mounts from a) virgin 
gland b) early pregnancy c) mid- to late pregnancy d) lactation. From Brisken et al. [3] 
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beginning of milk secretion into the alveoli [20, 22].  Females with normal mammary glands 
will lactate as long as the physical stimulus of nursing is present.  Within 24 hours of 
weaning, the mammary epithelium begins to undergo involution, an apoptotic clearing of 
alveoli from the mammary ductal structure.  The mammary gland is restored to its pre-
pregnancy state and will respond to the estrous cycle and pregnancy as it did previously [20].   
Mammary Stem Cells and Progenitors 
The functional definition of an adult stem cell is one that is capable of giving rise to 
the original tissue in vivo throughout repeated transplants [23].  These functional criteria of 
mutipotent differentiation and self-renewal have been observed in the normal function of 
the adult mammary gland.  The ability of the mammary gland to undergo repeated rounds of 
proliferation and remodeling in response to pregnancy has long been cited as evidence for 
the existence of mammary stem cells.  As early as 1959, transplantation studies of normal 
mammary glands have suggested that a single cell can give rise to a complete mammary gland 
[24].  In 1998, Smith et al. transplanted fragments of mammary glands infected with the 
Mouse Mammary Tumor Virus (MMTV) and, by analyzing the retroviral insertion site 
patterns of the newly grown glands, demonstrated that these mammary glands arose from a 
single cell [25].  While isolation of the mammary stem cell proved elusive, repeated attempts 
were made to characterize prospective mammary stem cells and progenitors by use of 
morphological analysis, stem cell markers from other tissue types (such as Sca-1), dye efflux 
assays, and cell lines with stem-like properties [26-29].   
 In 2006, two groups concurrently reported the isolation of a population containing 
mouse mammary stem cells.  Using CD29 (β1 integrin) or CD49f  (α6 integrin) in 
combination with CD24 (heat stable antigen), the Visvader and Eaves laboratories reported 
isolation of cell populations capable of forming a fully functional and serially transplantable 
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mammary gland.  Although single cells from both the CD24+/CD29+ and CD24+/CD49f+ 
populations could perform all mammary stem cell functions in vivo, neither set of markers 
purified mammary stem cells to homogeneity; the stem cell frequencies in the 
CD24+/CD29+ and CD24+/CD49f+ populations were calculated to be 1/64 and 1/100, 
respectively.  The CD24+/CD29+ and CD24+/CD49f+ populations demonstrated 
multipotent growth ability in vitro, as well as in vivo, forming colonies of varying sizes and 
morphologies in 2D growth assays, and developing multi-layered acini with occasional 
branched structures on reconstituted basement membrane (Matrigel™).  These stem cell-
containing populations were found to express high levels of myoepithelial/basal markers, 
such as CK14, SMA and p63.  The expression levels of CD29 and CD49f corresponded 
strongly, suggesting that the α6/β1 complex is highly expressed in mammary stem cells.  
Notably,  mammary stem cell populations were negative for steroid hormone receptors ER 
and PR [12, 13]. 
Figure 1-4. Mammary Epithelial Stem Cell Hierarchy. Known markers for mammary epithelial stemcells, progenitors 
and differentiated cells.  From Visvader et al. [1] 
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 In addition to labeling mammary stem cells, CD24, CD29 and CD49f have been 
used to isolate and characterize candidate mammary progenitors through in vitro assays.  
Progenitors are defined by the ability to give rise to at least one differentiated lineage and by 
the lack of self-renewal, which uniquely defines stem cells.  Shackleton et al. reported that 
only CD24+/CD29+ and CD24+/CD29lo cells could form colonies when grown in 2D 
colony assays on irradiated NIH3T3 feeder cells, and that CD24+/CD29lo-derived colonies 
were significantly fewer and smaller than those from CD24+/CD29+ cells.  CD24+/CD29lo 
and CD24+/CD49flo cells, when grown on Matrigel to form 3D colonies, gave rise to single- 
layer acini of cuboidal cells.  Both the CD24+/CD29lo and CD24+/CD49flo populations were 
initially reported as having no in vivo growth ability [12, 13].   
 These groundbreaking studies were followed by the discovery of additional markers 
for the purification and characterization of an increasing number of mammary epithelial cell 
types.  The CD24+/CD29lo population, which is believed to contain luminal progenitors, has 
been subdivided by expression of CD61 (β3 integrin) into a population of differentiated 
MECs (CD24+/CD29lo/CD61-) and mammary progenitors (CD24+/CD29lo/CD61+), based 
on in vitro colony forming ability.  Most CD24+/CD29lo/CD61+ progenitors were found to 
be ER negative [30].  Mammary epithelial cells also show different in vitro activity based on 
CD49b (α2 integrin) expression; CD24+/CD49b+ MECs were able to form colonies in vitro 
while CD24+/CD49blo MECs did not [31].  Expression of CD14 and c-Kit has been used to 
identify prospective alveolar progenitors.  The CD24+/CD29lo/CD14+/c-Kit- population 
expands during pregnancy and can give rise to lactogenic colonies in vitro [32, 33].  Stem cell 
antigen-1 (Sca-1), which has been used as a marker for hematopoietic stem cells, was 
originally believed to label mammary stem cells and/or progenitors[27].  However, later 
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studies proved the reverse, demonstrating that mammary stem cells were Sca-1- and that Sca-
1+ MECs were unable to repopulate the mammary gland in vivo [12, 34] (Figure 1-4). 
 Whereas a mammary epithelial stem cell can be defined by its ability to establish a 
fully functional mammary tree in vivo, the identification and characterization of mammary 
progenitors requires more complex analyses and assays.  Lineage-restricted progenitors that 
differentiated into myoepithelial and luminal MECs have been identified, principally as a 
result of in vitro assays [12, 13, 30, 31].  Although it was initially reported that CD24+/CD29lo 
and CD24+/CD49flo MECs were unable to form outgrowths in vivo, recent reports have 
demonstrated that these MECs can form small, branched mammary structures, when co-
injected with Matrigel into mammary fat pads.  Transplantation of CD24+/CD29+ cells, by 
contrast were unaffected by Matrigel[35, 36].  This evidence for Matrigel-dependent 
outgrowths suggest that the CD24+/CD29lo and CD24+/CD49flo populations contains 
multipotent progenitors that develop in vivo if provided with the additional stimuli present in 
Matrigel preparations.  Other groups have taken broader in vivo approaches, by transplanting 
mixed populations and extrapolating, based on the different mammary glandular structures 
grown, that the mammary gland contains unidentified progenitors which can give rise to 
mammary glands of different sizes and morphological characteristics [34, 37].   
Details about the in vivo activity of mammary stem cells and progenitors have been 
revealed by real-time tracking of MEC populations and lineage tracing.  Van Keymeulen et 
al. recently conducted extensive lineage tracing studies using transgenic mice that inducibly 
express fluorescent proteins driven by promoters for known mammary lineage markers, such 
as CK14, CK8 and CK18.  This study revealed that all mammary lineages derive from stem 
cells that express CK14 during embryogenesis.  Adult mammary epithelial cells were derived 
from lineage-restricted progenitors, including CK14-expressing myoepithelial progenitors 
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and CK8-expressing luminal progenitors, which were CD24+/CD29+ and CD24+/CD29lo, 
respectively.  Cells expressing CK5, which were also in the CD24+/CD29+ compartment, 
gave rise to myoepithelial cells specifically during pregnancy, while CK18-expressing cells 
were either committed progenitors or terminally differentiated MECs.  Unexpectedly, 
myoepithelial progenitors, which could give rise only to myoepithelial cells when in their 
native context, could be induced to adopt a multipotent progenitor phenotype when co-
transplanted with luminal cells.  This suggested that paracrine signaling can change the in vivo 
cell fate of a mammary progenitor.  This study demonstrated that lineage tracing in solid 
tissues can provide details of in vivo progenitor activity that might not be obtainable through 
repopulation studies [38].   
Mammary Stem Cells and Progenitors in Pregnancy 
 An early pregnancy is known to reduce the risk of breast cancer, a phenomenon that 
is believed to arise from a reduction in the proliferative potential of mammary stem cells and 
progenitors, making them less susceptible to oncogenic transformation [39].   Therefore, the 
mechanisms of mammary expansion during pregnancy and the identity of the cell types 
directly activated by pregnancy signaling is a matter of both medical and scientific interest 
[4].   
 In the mouse mammary gland, a plausible candidate for the mammary cell type 
directly activated by pregnancy is the same mammary stem cell that establishes the ductal 
architecture during puberty.  In this model, a single type of stem cell produces different 
structures (duct vs. alveoli) in response to the different signaling pathways that are active in 
each phase of mammary development.  Basal cells, which are contained within the 
CD24+/CD29+ mammary stem cell populationare seeded along the mammary ducts at 
regular intervals that suggest the spacing of alveoli[12, 13].  During pregnancy, the 
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CD24+/CD29+ compartment expands temporarily, peaking by day 12.5, at an 11-fold 
increase over what is found in virgin glands, and returning to its original fraction of the 
MEC population after involution.  However, the CD24+/CD29+ population in pregnant 
mice also loses 60% of its repopulation ability, which suggests that the size of stem and non-
stem populations within this compartment are increased [40].  In a real-time tracking study, 
the CD29/β1 integrin promoter was used to drive expression of luciferase in order to track 
the dynamics of mammary stem cells in vivo.  β1 integrin-luciferase expression labeled the 
entire CD24+/CD29+ compartment, which expands dramatically during pregnancy, 
increasing as a proportion of total MECs until the first week of lactation [41].  Additionally, 
the CD24+/CD49f+ stem cell population expands during the diestrus phase of the estrus 
cycle; it is during diestrus that side branches, which are thought to be either precursors to or 
stunted versions of alveoli, appear throughout the mammary tree [2].  However, these 
studies are limited by the markers used and it is remains possible that the expansion of these 
populations during the estrous cycle and pregnancy reflects increased numbers of non-stem 
MECs.   
 An alternative hypothesis is that different mammary stem cell/progenitor 
populations are responsible for the different modes of proliferation in puberty and 
pregnancy.  In this model, progenitors capable of giving rise to alveoli exist throughout the 
mammary gland but remain dormant until pregnancy.  The existence of pregnancy-specific 
progenitors has been suggested by a transplantation study of MECs from pregnancy 
mammary glands.  Limiting dilution transplants of MECs from pregnant mice gave rise to 
ductal-limited, lobule-limited, or bi-lineage outgrowths in vivo [37].  Further evidence for a 
pregnancy-specific progenitor has been provided by a lineage tracing study, in which MECs 
that are active during lactation were labeled using a lactation-specific transgene and a floxed 
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LacZ allele (WAP-cre/floxed Rosa26-LacZ).  Most labeled lactating cells underwent 
apoptosis during involution, but some MECs survived to produce LacZ-expressing alveoli in 
subsequent pregnancies [42].  These “parity induced MECs” (PI-MECs) were found to exist 
in pre-pubertal glands and were initially reported to have no in vivo repopulation ability, 
suggesting that pregnancy-activated progenitors are part of the normal mammary epithelium  
[43].  A later study found that PI-MECs contain mammary stem cells with in vivo 
repopulation ability, as well as alveolar progenitors.  However, the percentage of stem cells 
was comparatively small, and therefore this finding does not invalidate the evidence for 
alveolar-specific progenitors [44].  Additional support for the existence of a progenitor 
population with pregnancy-specific function is provided by work demonstrating that the 
mammary glands of mice expressing a defective form of cyclin D1 have reduced numbers of 
CD24+/CD49flo MECs.  When transplanted, cyclin D1-impaired CD24+/CD49flo MECs 
give rise to diminished mammary outgrowths with lobular defects, whereas CD24+/CD49flo 
MECs expressing wild-type cyclin D1 produce larger outgrowths with extensive alveolar 
development during pregnancy [35].  These data support the hypothesis that mammary stem 
cells are responsible for the development of the mammary gland during puberty, but a 
different population of MEC progenitors is responsible for mammary proliferation during 
pregnancy.  
The Mouse Mammary Tumor Virus (MMTV) Promoter 
 Mouse Mammary Tumor Virus (MMTV) provided one of the earliest mouse models 
of cancer.  The first description of a mouse mammary tumor, which might have been caused 
by MMTV, dates back to 1854 [45].  In subsequent decades, an apparently inherited mouse 
mammary cancer, which could sometimes be “transplanted”, became established as an 
important mouse model of cancer.  In 1933, researchers at Jackson Labs identified the cause 
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of this mammary cancer as a milk-borne “extrachromosomal factor” that eventually was 
classified as a retrovirus [45].  Unlike the Rous Sarcoma Virus, MMTV did not cause cancer 
by expression of an oncogene carried within its own genome, but by insertion of the 
provirus near to and activation of critical proto-oncogenes including Wnt1, Notch and 
FGF3 [46-48].   
 The MMTV long terminal repeat (MMTV-LTR), often termed the MMTV promoter, 
was cloned in 1981, enabling structural analysis of its 1.3 kb sequence [49].  The MMTV 
promoter has binding sites for NF1 (nuclear factor 1) and Oct-1, as well as numerous 
hormone responsive elements, which bind to glucocorticoid receptor (GR) and progesterone 
receptor (PR) [50-53]. (Figure 1-5) These hormone responsive elements were found to be 
the mechanism behind the activity of the MMTV promoter in vivo [5, 54].  Glucocorticoids 
and progesterone can bind to and directly activate the MMTV promoter, but MMTV activity 
is also heavily dependent on nucleosome position [55-58].   
 The MMTV promoter is frequently used to express transgenes in the mouse 
mammary gland.  Although other mammary-specific promoters exist, their timing and 
activity can reduce their utility.  The beta-lactoglobulin (BLG) promoter drives gene 
expression at very low levels until pregnancy and the whey-acidic protein (WAP) promoter is 
active during late pregnancy and lactation, also with minimal activity before pregnancy [59, 
60].  By contrast, the MMTV promoter is expressed early in mammary development and 
Figure 1-5. MMTV Promoter Structure. The MMTV promoter contains at least four hormone responsiveelements 
(HREs) which bind to progesterone receptor and glucocorticoid receptor.   From Beato et al. [5] 
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does not require pregnancy or lactation for full activation, lowering the technical barriers for 
its use [60-62].   
 Since the development of the MMTV-myc mouse in 1984, dozens of mouse models 
of breast cancer have utilized the MMTV promoter, both directly and indirectly [63].  
Although these models have provided valuable insights into mammary neoplasia, tumor 
invasion and metastasis, their dependence on the incompletely characterized activity of a 
viral promoter should be considered when interpreting these data.  MMTV-driven 
transgenes are usually inserted randomly rather than being knocked in at a specific location.  
Consequently, expression patterns can vary between different MMTV-driven clones, 
depending on the insertion site or genetic background [60, 64].  The MMTV promoter also 
is active in non-mammary tissues, including the salivary gland, seminal vesicles and B-cells 
[61, 65].  Expression in the lymphoid system is a particular handicap and has resulted in 
transgenic mice that die of lymphoma before they can develop mammary tumors from an 
MMTV-driven oncogene [66, 67].   
Nevertheless, mice expressing MMTV-driven transgenes have provided some 
information about MMTV promoter activity during mammary development.  Although the 
MMTV promoter is active in the mammary gland before and during puberty [60], studies of 
MMTV-driven tumor models have found that multiple pregnancies result in decreased 
latency and increased size and metastatic potential of tumors, suggesting that promoter 
activity is upregulated during pregnancy and lactation [68-70].  Some studies have suggested 
that MMTV is active in all MECs, but this is unlikely for several reasons [65].  Given that the 
MMTV promoter is responsive to steroid hormone receptors and MECs vary widely in 
hormone receptor status, it is unlikely that the MMTV promoter is expressed equally across 
all MECs [51, 56].   MMTV activity also depends on nucleosome position, and therefore is 
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likely to be sensitive to the chromatin state in any given cell [71].  Further study is required 
to fully elucidate the dynamics of MMTV promoter activity in the transgenic mammary 
gland.    
Identification of Prospective Stem Cells by Label Retention 
 Prospective adult stem cells and stem cell niches have been identified through a 
variety of methods, including dye exclusion, drug resistance, expression of known stem cell 
markers, in vitro proliferation, and label retention.  These assays rely on the hypothetical 
properties of adult stem cells, and are used mainly in tissue systems where the stem cell 
hierarchy is unknown or incomplete, or where no definitive in vivo reconstitution assays exist.   
 Pulse-chase studies of various tissues have identified cell populations that are able to 
maintain a DNA-based label significantly longer than the bulk of the tissue.  Label retention 
is hypothesized to be a property of adult stem cells with two possible explanations.  One is 
that stem cells divide infrequently, preventing the dilution of label through successive 
mitoses.  The alternative explanation is that when a stem cell undergoes asymmetric division, 
producing a stem cell and a more differentiated cell, the older template DNA is retained by 
the stem cell, allowing for maintenance of a strong signal through many divisions.  This 
theory, known as the parental strand or immortal strand hypothesis, suggests an unknown 
but fundamental difference in the mechanisms of DNA segregation in stem cells.  In both of 
these models, label retention is hypothesized to be a mechanism for maintaining genome 
integrity [72-74] (Figure 1-6). 
 Label retention studies have been conducted to identify the stem cells and stem cell 
niches in various organ systems, most notably in the small intestine and the epidermis [75-
77].  In the small intestine experiments, mice were irradiated to clear the small intestinal  
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epithelium and to activate stem cell proliferation, then given extensive treatments of 
radiolabeled thymidine or BrdU (bromodeoxyuridine), and sacrificed at intervals to identify 
and locate the label retaining cells (LRCs).  LRCs were found near the bottom of the small 
intestinal crypts, at specific locations.  Further studies demonstrated that these cells were also 
actively cycling, which provided the first evidence of parental strand retention in an in vivo 
mammalian system [72].  Different intestinal cells recently have been identified as stem cell 
candidates based on separate criteria, including expression of potential stem cell markers 
such as Lgr5 and telomerase, and in vitro proliferation assays, raising questions over the role 
of LRCs in the small intestinal stem cell hierarchy [78-80].  In the mammalian epidermis, 
DNA label retention identified the hair follicle bulge as the repository of LRCs and a 
potential stem cell niche [81, 82]; epidermal LRCs had a higher proliferative potential than 
non-LRCs in ex vivo cultures and proliferated in response to damage [83, 84].  The epidermal 
bulge was verified as a stem cell niche when Tumbar et al. isolated fluorescently-tagged 
epidermal LRCs and demonstrated their stem cell activity in vivo [85].   
In the mammary gland, label retention studies have been applied to the task of 
identifying mammary gland stem cells and tracing stem cell activity throughout mammary 
development.  However, the dynamics of the mammary gland, which cycles slowly in 
comparison to the rapid turnover of the small intestine and epidermis, has resulted in the 
development of different pulse-chase methods.  To stimulate label dilution, some groups 
transplanted labeled MECs, triggering a fresh round of mammary proliferation in the 
recipient fat pad.  In other studies, pregnancy was induced as a method of label dilution [29, 
86-88].  
In these studies, mammary LRCs were located in the terminal end buds and along 
the mammary ducts at regular intervals [29].  A more detailed study found LRCs made up 
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4% of the luminal cells, 20% of the myoepithelial cells and 28% of the basal cell populations 
[88].  To examine the kinetics of mammary LRCs, Smith and colleagues administered a 
second DNA label to mammary glands that had already undergone an initial pulse-chase 
protocol.  Mammary cells already retaining the first label were found to incorporate the 
second DNA label, indicating that they were actively undergoing mitosis; this study raised 
the possibility of parental strand retention in the mammary epithelium [86].  In contrast to 
the mammary stem cells isolated by Shackleton et al. and Stingl et al., 40% of mammary 
LRCs were found to express ER and PR [12, 13, 89].  Mammary LRCs were also found to be 
actively cycling during pregnancy, suggesting a role for them during alveologenesis [88, 90].  
Welm et al. found that MECs exhibiting other hypothesized stem cell characteristics, such as 
Sca-1 expression and dye efflux, were found to be enriched for mammary LRCs [27]; 
Figure 1-6. The Parental Strand Hypothesis. During an asymetric stem cell division, the older “parental” DNA strands 
are segregated into the daughter cell which remains a stem cell.A division which produces two stem cells would result in the 
unsegregated distribution of  parental DNA.  Immortal/Parental strand segregation is hypothesized to be the mechanism 
behind label retention in some somatic stem cells.  From Smalley and Ashworth [4] 
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however, later studies found that dye efflux does not correlate with stem cell activity, and 
that Sca-1 in fact labeled differentiated mammary cells [12, 13] .   
These studies have raised interesting questions about the mechanisms of mammary 
proliferation and development.  The continued cycling of label-retaining cells suggests that 
parental strand segregation is in operation in mammary epithelial cells.  LRC expression of 
hormone receptors and Sca-1, as well as their activity during pregnancy  suggest that LRCs 
might not be stem cells, but progenitors or stem cells with a pregnancy-specific function 
[12].  Further study of mammary LRCs is required to elucidate their function in the 
mammary gland.   
The critical weakness of label retention as a method of identifying somatic stem cells 
is that use of a DNA-based label such as BrdU or tritiated thymidine precludes the isolation 
of live LRCs for transplantation assays.  This limitation has been resolved with the 
development of a transgenic mouse carrying histone 2b/eGFP fusion (H2BGFP) under the 
control of a tetracycline responsive regulatory element.  When crossed with a strain 
expressing the tetracycline transactivator, H2BGFP can be turned on and off by 
administering or withholding tetracycline or doxycycline, resulting in fluorescently labeled 
cells that can be isolated by FACS [85].  Functional homology between DNA label retention 
assays and histone label retention assays is probable but not conclusively confirmed.  There 
is conflicting evidence over whether new and old histones distribute evenly or segregate 
preferentially between daughter strands during DNA synthesis, so no conclusions can be 
drawn about a “parental histone” hypothesis on current evidence [91-93].  There is also 
evidence that H2B proteins are continuously synthesized and exchanged without the 
stimulus of DNA replication, a phenomenon that could alter the kinetics of H2BGFP label 
retention [94].  However, when the H2BGFP label retention system was used to study skin 
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development, histone LRCs were found in the epidermal bulge, precisely as DNA LRCs had 
been.  Histone-retaining bulge cells are able to regrow the original epidermis in transplant 
and proliferate in response to wounding.  These histone LRCs were also found to express 
low levels of proliferation-associated transcripts, suggesting that the mechanism for histone 
label retention is infrequent mitosis [85, 95].     
Subsequently, the transgenic H2BGFP system has been used to identify prospective 
adult stem cells in the kidney papilla and the ovarian coelomic epithelium [96, 97].   
Interestingly, H2BGFP label retention in the hematopoietic system was found to correlate 
with higher repopulation potential and stem cell markers; this result was unexpected because 
a previous study had reported that hematopoietic stem cells did not retain a BrdU label [98, 
99].  These data demonstrate that H2BGFP label retention is a powerful tool in the isolation 
of stem cells and identification of stem cell niches.   
Contributions of this Thesis  
The goal of my studies was to identify and assess prospective mammary epithelial 
stem cell and progenitor populations, building upon previous knowledge by examining 
known and potentially novel members of the mammary stem cell hierarchy.  I have provided 
evidence for the existence of a novel pregnancy-activated multipotent mammary progenitor.   
 Chapter 2 describes the testing of four different transgenic models of inducible 
H2BGFP expression to identify label-retaining cells in the mouse mammary gland.  The 
MMTVrtTA line[65] proved to be most amenable for labeling MECs with H2BGFP.  
However, I found that in the MMTVrtTA/H2BGFP model, label retention does not enrich 
for cells with mammary repopulating ability.  However, these studies revealed the existence 
of an H2BGFP-labeled subpopulation of the CD24+/CD29lo compartment that has in vivo 
repopulation ability.   
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 Chapter 3 evaluates the stem cell and progenitor activity of mammary epithelial 
subpopulations identified by MMTVrtTA/H2BGFP expression.  I found that the 
H2BGFP+/CD24+/CD29lo population contains multipotent progenitors with the ability to 
form mammary glandular structures in vivo.  The repopulation ability of 
H2BGFP+/CD24+/CD29lo cells increases five- to ten-fold when the transplant recipient is 
made pregnant, providing evidence that these progenitors are preferentially activated by 
pregnancy.  Expression analysis supports the conclusion that H2BGFP+/CD24+/CD29lo 
cells are distinct from H2BGFP-/CD24+/CD29lo cells.  H2BGFP+/CD24+/CD29lo cells 
express lower levels of transcripts for genes involved in mammary and differentiation and 
development than H2BGFP-/CD24+/CD29lo cells, contributing to the evidence that 
H2BGFP+/CD24+/CD29lo contains mammary progenitors.   
 The Appendix describes the analysis and testing of candidate cell surface markers for 
isolation of the H2BGFP+/CD24+/CD29lo population.  CD14 is identified as a potential 
marker for pregnancy-activated progenitors.   
 This thesis expands on previous work on the mammary stem cell hierarchy by 
providing evidence for a pregnancy-specific progenitor in vivo.  This work supports the 
hypothesis that mammary cells responsible for pregnancy-induced expansion are different 
from the stem cells and progenitors that establish the mammary gland architecture during 
puberty.   
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Chapter 2 Materials & Methods  
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Mice. CMVrtTA (#003273) [100] and MMTVtTA (#002618) [101] transgenic strains were 
purchased from Jackson labs.  Rosa26rtTA mice were donate by R. Jaenisch [102].  
MMTVrtTA mice were donated by L. Chodosh [65].  H2BGFP mice in the CD-1 
background were provided by E. Fuchs [85].  H2BGFP was backcrossed onto the FVB 
strain for a minimum of 5 generations prior to crossing with MMTVrtTA and CMVrtTA 
mice.  To induce transgene expression, breeders and experimental mice were maintained on 
2 mg/ml doxycycline (Research Products International 50213285).  Mouse colonies were 
maintained according to federal, state and institutional regulations.   
Genotyping. Tail biopsies were obtained from transgenic mice and dissolved in 0.5 ml tail 
lysis buffer (10 mM Tris + 100 mM NaCL + 10 mM EDTA + 0.5% SDS + 1 mg/ml 
Proteinase K) at 60ºC for >4 hours.  After proteinase K treatment, 250 μl 6 M NaCL was 
added and  each sample, inverted 2-3 times and incubated on ice for 10 minutes.  Samples 
were clarified at 10,000 rpm in a microcentrifuge for 10 minutes.  Supernatant was added to 
650 μl of isopropanol and inverted 2-3 times.  Samples were centrifuged at the highest speed 
in a microcentrifuge for 10 minutes.  Supernatant was decanted, precipitates were air-dried 
and dissolved in 100 μl ddH2O.  For H2BGFP mice: GFP-F: 5’- 
GCAAGGGCGAGGAGCTGTTCACC-3’, GFP-R: 5’- 
GGCGAGCTGCACGCTGCCGTCCTC-3’, expected band size 500 bp.  For all tTA/rtTA 
strains: tTA-F: 5’- CgCTgTggggCATTTTACTTTAg -3’, tTA-R: 5’- 
CATgTCCAgATCgAAATCgTC-3’, expected band size 450.  Control genotyping PCR: 
TCRD-F: 5’- CAAATgTTgCTTgTCTggTg -3, TCRD-R: 5’- gTCAgTCgAgTgCACAgTTT -
3’, expected band size 200 bp.  All genotyping PCRs were run as follows: 95ºC 5 min, 95 ºC 
45 sec, 58 ºC 45 sec, 72 ºC 60 sec, repeat from second 95 ºC step 25X, 72 ºC 5 min, 4 ºC 
final.  PCR products were run on a 2% agarose gel.   
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Mammary gland harvesting and preparation. Mice were sacrificed and harvested for 
mammary glands.  Lymph nodes were removed from inguinal gland #4.  Mammary tissue 
was manually minced, placed in culture medium (DMEM/F12 + 500 ng/ml hydrocortisone 
+ 10 ng/ml EGF + 10μg/ml insulin + 20 ng/ml cholera toxin + 1% Pen/Strep) [12] with 
600 U/ml collagenase and 200 U/ml hyaluronidase and shaken at 37ºC for 1-1.5 hrs.  
Digested tissue was pelleted and resuspended in a mixture of .25% Trypsin-EDTA (Gibco 
#15050-065), 5 mg/ml dispase (Roche 04942078001) and .1 mg/ml DNAse (Sigma # 
D5319) for 5-7 minutes.  Trypsin digestion was quenched with DMEM/F12+10% FBS.  
Cells were pelleted and resuspended in Tris-buffered .64% NH3Cl for 3 minutes on ice, and 
filtered sequentially through 100um and 40um filters.   
Flow Cytometry. Single cell suspensions were blocked in FACS buffer (PBS + 2 mM 
EDTA + 0.1% BSA) containing 1:25 normal rat serum (eBioscience 24-5555) and 1:25 anti-
mouse FC receptor block (eBioscience 16-0161) for 10 minutes, stained in FACS buffer 
containing directly conjugated antibodies for 20 minutes.  Cells were resuspended in FACS 
buffer (containing 1μg/ml DAPI for viability analysis) and analyzed on a BD Aria II or 
FACS Canto II using BD Aria software.  Antibodies used for flow cytometry included 
CD24•PE (eBioscience 12-0242), CD29•APC (Biolegend 102215), CD49f •Biotin 
(eBioscience 13-0495), CD31•PeCy7 (eBioscience 25-0311), CD45•PeCy7 (eBioscience 25-
0451), Ter119•PeCy7 (eBioscience 25-5921) and Streptavidin APC-eFluor 780 (eBioscience 
47-4317-82). All populations were double-sorted with doublet discrimination to ensure 
purity, and were recounted by hemocytometer post-sort to obtain an accurate cell count.   
Antibodies used for flow cytometry studies described in the Appendix included AlCam•PE 
(eBioscience 12-1661-81), amphiregulin (R&D BAF989), CD14 (eBioscience 13-0141-80), 
CD24 (eBioscience 13-0242-80 ), CD44 (eBioscience 13-0441-81), CD49b (eBioscience 13-
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5971-80), CD49f (eBioscience 13-0495), CD55 (eBioscience 12-0559-71), CD61 
(eBioscience 13-0611-80), CD86 (eBioscience 13-0862-80), CD138/Syndecan•PE (R&D 
FAB2966P), CD164 (R&D BAF3118), c-Kit (eBioscience 13-1171-81), CXCL16 (R&D 
BAF503), E-cadherin (eBioscience 13-3249-80), EpCAM (eBioscience 13-5791-80), 
FGFR2•PE (R&D FAB684A), IL1R1•PE (R&D FAB7712P), IL33 (R&D BAF3626), 
Jag1•PE (Ebioscience 12-3391-80), Muc1 (AbCam ab13970), Osteoactivin (R&D BAF2330), 
PRLR (R&D BAF1445), and Sca-1 (eBioscience), Secondary antibodies included 
Streptavidin APC-eFluor 780 (eBioscience 47-4317-82), Anti-rabbit Alexa750 (Invitrogen A-
21039) 
Mammary fat pad clearing and transplantation. Sorted cells were counted and 
resuspended in growth factor-reduced Matrigel (BD Biosciences 354230) for injection.  
Three week-old female mice between 10-12g were obtained from Charles River 
Laboratories.  Mice were anesthetized with 4mg/10g body weight Avertin (Sigma #T48402); 
abdomens were shaved and cleaned with 70% ethanol and Betadine.  An inverted Y-shaped 
incision was made along the thoracic-inguinal region and mammary glands were exposed.  
The nipple and mammary artery connecting the #4 and #5 glands were cauterized.  
Endogenous epithelium was removed from the inguinal (#4) mammary glands of 3 week-old 
female mice; removed epithelium was fixed and stained with carmine alum to verify 
complete clearing.  Cells were injected into the cleared fat pad pads in 10 μl volumes, using a 
Hamilton syringe.  Incisions were then closed with wound clips.  Mice were administered 
with two doses of 0.5 mg/kg body weight Buprenorphine (Webster Vetinary #07-867-1196) 
in the 24 hours after surgery.  Mammary fat pads were harvested 6 weeks after injection, 
unless pregnancy induction required an earlier harvest date.  Harvested tissues were either 
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whole mounted and scored for mammary outgrowths or dissociated for re-analysis and/or 
serial transplants. [103]   
Pregnancy induction. Adult males were housed with post-transplant females 3-4 weeks 
after surgery.  Plugs were checked daily to verify the timing of pregnancies.  Females were 
sacrificed and mammary glands were harvested between day 14-20 of the pregnancy.     
Whole Mounts. Mice were sacrificed and #4 mammary glands were dissected, spread onto 
slides, air-dried for 5 minues and fixed in Methyl Carnoy (1:3:6 glacial acetic acid, 
chloroform, methanol) for 4-24 hrs.  Tissues were treated with successive washes of 100%, 
75%, 50% and 25% EtOH, distilled water, and then stained overnight in carmine alum 
staining solution (2 g/l carmine + 5 g/l aluminum potassium sulfate).  Mammary glands 
were dehydrated in washes of 70% and 100% EtOH, washed twice in xylenes and then 
mounted in Permount (Fisher SP15-100) and coverslipped.  Whole mounts were scored and 
imaged using a dissecting microscope [103].  All mammary outgrowths observed by carmine 
alum staining were confirmed by tissue sectioning and immunostaining.   
Statistical Analysis of Transplant Data. MRU frequencies were calculated using single-hit 
Poisson statistical methods [104].  Poisson9 software developed by the Iscov lab was used 
for these analyses.  (http://www.uhnresearch.ca/labs/iscove/homebrew.html)   
RNA Isolation and Microarray Analysis.  RNA was harvested from sorted cells using the 
Qiagen RNeasy Micro Kit (Qiagen 74004), amplified using the NuGen RNA amplification 
system, and analyzed for differences in gene expression on the Illumina Mouse platform.   
qPCR.  For qPCR confirmation of the microarray experiments, RNA was harvested from 
sorted cells using the Qiagen RNeasy Micro Kit and amplified using the NuGen RNA 
amplification system, and labeled using the SYBR Green Master Mix (Applied Biosystems 
4309155).  qPCR reactions were run on an Applied Biosystems 7900HT.  qPCR primers 
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were: Esr1-F 5’- tgggcgacattcttctcaa-3’, Esr1-R 5’-tggaccagaggtacatccatt-3’, PRLR-F 5’- 
ggttatagcatgatgacctgcat-3’, PRLR-R 5’- cagttcttcagacttgcccttc -3’, AREG-F 5’- 
gcgaatgcagatacatcgag-3’, AREG-R 5’- ccacaccgttcaccaaagta-3’, FGFR2-F 5’-
gagcgctgccattcaagt-3’, FGFR2-R 5’-ttgctgttgttactgctgttcc-3’, Muc1-F 5’-ctgttcaccaccaccatgac-
3’, Muc1-R 5’-cttggaagggcaagaaaacc-3’, Wnt5a-F 5’- acgcttcgcttgaattcct -3’, Wnt5a-R 5’-
cccgggcttaatattccaa-3’, Il1R1-F 5’-cgaaccgtgaacaacacaaa-3’, Il1R1-R 5’- aatctccagcgacagcagag-
3’, Cav1-F 5’- acgacgacgtggtcaagatt-3’, Cav1-R 5’-cacagtgaaggtggtgaagc-3’, Robo1-F 5’-
ccacccaccagacaggag-3’, Robo1-R 5’-gtatgaggtggggaaattgg-3’, Ly6a-F 5’- cccctaccctgatggagtct-
3’, Ly6a-R 5’- tgttctttactttccttgtttgagaa-3’ 
3D Matrigel assays. Matrigel™ (BD Biosciences 354230) was pipetted into the wells of an 
8-well chamber slide and allowed to polymerize for 15 minutes at 37ºC.  Sorted MECs were 
plated at 1,000 cells/well in growth media (DMEM/F12 + 500 ng/ml hydrocortisone + 10 
ng/ml EGF + 10 μg/ml insulin + 20 ng/ml cholera toxin + 1% Pen/Strep + 1% FCS) for 
1 week, and differentiation media (DMEM/F12 + 5 μg/ml insulin + 500 ng/ml 
hydrocortisone + 5 μg/ml prolactin + 1% FCS) [12].   
Immunostaining. For whole tissue sections, mammary glands were either fixed in Methyl 
Carnoy, or, if stained previously with carmine alum, unmounted by washing in xylenes.  
Tissues were paraffin-embedded and sectioned.  Slides were deparaffinized in xylenes, and 
rehydrated in decreasing concentrations of EtOH, followed by 20 minutes boiling in 10 mM 
sodium citrate for antigen retrieval.  For frozen sections, freshly dissected tissues were 
mounted in OCT (Sakura 4583), flash-frozen in liquid nitrogen and sectioned.   
For cytospins and colony assays, slides and coverslips were fixed in 4% PFA and 
rinsed with PBS for staining.  3D matrigel cultures were fixed and stained as described by 
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Debnath et al[105].  Primary antibody staining was performed at 4ºC overnight; secondary 
antibody staining was performed at room temperature for 1 hr.   
Primary antibodies used for immunostaining included cytokeratin 8/TROMA-1 
(Developmental Studies Hybridoma Bank TROMA-I-c), cytokeratin 18 (Covance SIG-
3466), cytokeratin 14 (Lifespan Biosciences LS-C22637), p63 (Biolegend 619001), β1 integrin 
(BD Biosciences 550531), estrogen receptor (Santa Cruz SC-542), progesterone receptor 
(DAKO A0098), glucocorticoid receptor (Santa Cruz SC-1004), milk (Nordic 
Immunological Laboratories RAM/MSP), and amphiregulin (Santa Cruz sc-25436).  All 
secondary antibodies were Alexa Fluor-conjugatedantibodies from Invitrogen.   
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Chapter 3 Histone Label Retention in 
the Mouse Mammary Gland   
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Introduction  
 Adult stem cells have been observed to retain a DNA-based label for extended 
periods of time.  This has been hypothesized to be either the result of relative mitotic 
quiescence, or due to stem cell retention of the older “parental” DNA strand.  Label 
retention has been utilized to identify adult stem cells/progenitors and locate stem cell 
niches in several tissue systems [72, 77].  In the mammary gland, label retaining cells (LRCs) 
have been found preferentially in the myoepithelial/basal compartment, which is 
hypothesized to contain mammary stem cells [88].  Although their activity in mammary 
development is still unclear, mammary LRCs have been observed to be actively undergoing 
mitosis, which suggests parental strand retention, and might play a role in alveologenesis [86, 
90].   
 The major limitation of the DNA label retention system is that it precludes isolation 
of live LRCs for functional characterization.  These DNA-based labels also damage DNA 
and can stimulate repair pathways and/or cell division [106].  To enable isolation of live 
LRCs by fluorescence-activated cell sorting (FACS), Tumbar et al. developed a transgenic 
mouse carrying the tetracycline-inducible histone 2B/eGFP fusion (H2BGFP), which can be 
regulated in a tissue- or cell-specific manner by crossing to another strain expressing the 
tetracycline transactivator driven by a specific promoter [85].   This technique has been 
effective in isolating prospective adult stem cells in the epidermis, the ovarian coelomic 
epithelium, the kidney papilla and the hematopoietic system [85, 96, 97, 99].  
To identify and isolate prospective stem cells and progenitors through label retention 
in the mammary gland, I crossed H2BGFP transgenic mice with four different inducible 
lines, one that expresses the tetracycline transactivator, MMTVtTA [101, 107] and   
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Figure 3- 1. H2BGFP induction under control of tetracycline transactivator vs. reverse tetracycline transactivator.  
Administration of doxycycline turns off transgene expression in tTA systems (left) and turns on transgene expression in 
rtTA systems (right). 
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and three that express the reverse tetracycline transactivator, CMVrtTA [100], Rosa26rtTA 
[102], MMTVrtTA [65] (Figure 3-1).  (Tetracycline transactivator is inhibited by 
tetracycline/doxycycline treatment, and reverse tetracycline transactivator is activated by 
these drugs.)  These strains were selected for their probable expression in mammary 
epithelial cells.  Double transgenic mice were assessed for H2BGFP induction by 
immunostaining and flow cytometry.  Transgene expression was induced until four weeks 
after birth, and then turned off for six to eight weeks, allowing the high level of mammary 
proliferation during puberty to act as a “chase” period (Figure 2-2).  Label retaining cells 
were isolated from the mammary gland by FACS and were analyzed for stem cell 
characteristics and activity.  This chapter describes the results of these crosses and the 
characterization of H2BGFP label-retaining cells in the mammary gland.   
Results 
CMVrtTA does not induce H2BGFP expression in the mammary gland 
 The cytomegalovirus (CMV) promoter is known for its high activity in many tissue 
types and is therefore commonly used to express target genes in both in vitro and in vivo 
studies [108].  Kistner et al. developed a transgenic mouse expressing the reverse tetracycline 
Figure 3- 2. H2BGFP label retention in the mammary gland.  H2BGFP expression is induced in the mammary gland 
until four weeks after birth (left) and turned off for 6-8 weeks.  At the end of puberty, H2BGFP LRCs remain in the adult 
mammary gland (right). 
32 
 
transactivator under control of the CMV promoter.  This transgene is reported to induce 
tetracycline-responsive genes in the pancreas, kidney, stomach, muscle, thymus, heart and 
tongue; no previous studies of this mouse tested for CMVrtTA activity in the mammary 
gland [100].   
 I crossed the CMVrtTA strain to the H2BGFP transgenic mouse.  Because this 
transgene expresses the reverse tetracycline transactivator, which is activated by tetracycline 
or doxycycline treatment, I maximized H2BGFP induction by treating experimental breeders 
and pups with doxycycline throughout breeding, pregnancy, lactation, and after weaning, 
until sacrifice.  At four weeks post-birth, female double transgenic mice were sacrificed.  A 
selection of tissues was harvested and cut for frozen sections for direct assessment of 
endogenous H2BGFP expression.  As controls, tissues were analyzed from doxycycline-
treated H2BGFP single transgenic mice and double transgenic mice that had not received 
any drug.   
 H2BGFP expression was assessed by monitoring direct fluorescence of frozen tissue 
sections with DAPI and phalloidin counterstaining.  Mosaic H2BGFP expression was 
observed in the thymus, stomach, pancreas, kidney and muscle, but not in the lung, liver, 
spleen and mammary gland (Figure 3-3).  No H2BGFP expression was detected in the 
tissues of untreated mice or single transgenic mice (data not shown).  The pattern of 
H2BGFP detection in the thymus, stomach, pancreas, kidney and muscle was consistent 
with previous reports, indicating that the absence of H2BGFP detection in the lung, liver, 
spleen and mammary gland were not due to technical issues in my analysis.   
 To ask whether H2BGFP was expressed at levels below the threshold of 
microscopic visualization, mammary glands were harvested from CMVrtTA/H2BGFP mice,  
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Figure 3- 3. CMVrtTA/H2BGFP expression in various tissues. H2BGFP expression at 4 weeksin a) mammary gland 
b) spleen c) thymus d) lung e) liver f) stomach g) pancreas h) kidney i) muscle 
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mammary glands from induced double transgenic four week-old females were dissociated 
into a single cell suspension and analyzed by flow cytometry.  There was no evidence of 
H2BGFP expression in CMVrtTA/H2BGFP mice when compared with either single 
transgenic mice or double transgenic mice that had received no doxycycline treatment 
(Figure 3-4).  I therefore discontinued use of the CMVrtTA mouse model.   
MMTVtTA expression and label retention in the mammary gland 
 The MMTV promoter is frequently used to direct transgene expression in the 
mammary gland.  To create an inducible system for transgene expression in the mammary 
gland, Furth et al. developed the MMTVtTA mouse, which expresses the tetracycline 
transactivator under control of the MMTV promoter.  This transgenic mouse was found to 
have tetracycline transactivator activity in the seminal vesicle, salivary gland, epidermis and 
mammary gland [107].  Later studies demonstrated that MMTVtTA also is expressed in 
lymphoid cells [66].   
 To express H2BGFP inducibly in the mammary gland for label retention studies, I 
crossed the MMTVtTA transgenic strain with H2BGFP mice.  Because this system 
expresses the tetracycline transactivator, which is deactivated by tetracycline or doxycycline 
Figure 3- 4. CMVrtTA/H2BGFP expression in the mammary gland.  Mammary glands were harvested, dissociated 
and analyzed by flow cytometry from four week old transgenic females which were a) H2BGFP single transgenic b) 
CMVrtTA/H2BGFP, no doxycycline treatment c) CMVrtTA 
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treatment, mice were kept off of doxycycline until the start of the chase period for the label 
retention experiment.  Tissues were assessed by immunofluorescence and flow cytometry for 
H2BGFP expression at four weeks after birth, to measure transgene induction, and after 6 
weeks of doxycycline treatment, to measure label retention.  By flow cytometry, 
MMTVtTA/H2BGFP induction was detected in 5.8±2.1% of MECs, which was reduced to 
0.8±0.2% after six weeks of doxycycline treatment (Figure 3-6).  By immunofluorescence, no 
correlation was observed between CK14 or CK8 expression and H2BGFP induction or label 
retention (Figure 3-5).  H2BGFP induction and label retention also were observed in 
hematopoietic tissues at levels higher than those found in the mammary gland.  
 Although initial experiments with the MMTVtTA mouse were promising, I 
ultimately discarded this model of H2BGFP induction because the relatively high level of 
H2BGFP expression in the lymphoid system compared to the mammary gland made the 
MMTVtTA system unsuitable for further use.  Although the flow cytometry assays are gated 
to exclude hematopoietic lineages, label retention assays necessarily isolate very small 
populations and are therefore particularly sensitive to contamination.  Additionally, in 
parallel crosses of other tetracycline transactivator strains with H2BGFP, I found that 
crosses between H2BGFP and the MMTVrtTA or the Rosa26rtTA strains resulted in  
Figure 3- 5 MMTVtTA/H2BGFP Expression and Label Retention in the Mammary Gland - 
Immunofluorescence. Mammary glands were harvested and stained from female mice a) H2BGFP single transgenic b) 
MMTVtTA/H2BGFP, four weeks induction c) MMTVtTA/H2BGFP, 4 weeks induction 
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Figure 3- 6. MMTVtTA/H2BGFP Induction and Label Retention – Flow Cytometry. Representative plots for flow 
cytometric analysis of MMTVtTA/H2BGFP model.. a) Mammary gland, H2BGFP single transgenic b) Mammary gland, 
MMTVtTA/H2BGFP, 4 weeks induction c) Mammary gland, MMTVtTA/H2BGFP, 4 weeks induction + 6 weeks chase 
d) Bone marrow, H2BGFP single transgenic e) Bone marrow, MMTVtTA/H2BGFP, 4 weeks induction f) Bone marrow, 
MMTVtTA/H2BGFP, 4 weeks induction,+ 6 weeks chase g) Spleen, H2BGFP single transgenic h) Spleen, 
MMTVtTA/H2BGFP, 4 weeks induction i) Spleen, MMTVtTA/H2BGFP, 4 weeks induction + 6 weeks chase 
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significantly higher levels of transgene induction in the mammary gland, making those two 
models better suited for my experiments than MMTVtTA.   
Rosa26rtTA/H2BGFP expression and label retention in the mammary gland 
 The Rosa26 reverse tetracycline transactivator (Rosa26rtTA) mouse was developed 
to allow inducible expression of transgenes in multiple tissues at different stages of 
development [102].  To ask whether Rosa26rtTA could induce H2BGFP expression in the 
mammary gland, I crossed the Rosa26rtTA mouse with the H2BGFP strain.   
 To determine which tissues expressed H2BGFP under the control of Rosa26rtTA, I 
harvested tissues from four week-old female mice that had undergone constant doxycycline 
treatment.  H2BGFP fluorescence was directly visualized in frozen sections with a DAPI 
and phalloidin counterstain (Figure 3-7).  H2BGFP expression was observed in the 
mammary gland, lung, liver, muscle, small intestine, pancreas, kidney, spleen, ovary and 
fallopian tubes.  This expression pattern is in accordance with findings reported previously 
for the Rosa26rtTA transgenic mouse[102, 109].     
 Mammary glands from four week-old female double transgenics undergoing 
doxycycline treatment were harvested and analyzed by flow cytometry and 
immunofluorescence.  By flow cytometry, H2BGFP expression was detected in 8.6±1.2% of 
MECs.  In the CD24+/CD29+ compartment, which contains mammary stem cells, 13±9.3% 
of MECs were H2BGFP+ and in the CD24+/CD29lo progenitor compartment, 4±2.5% of 
MECs were H2BGFP+ (Figure 3-8).  Given that 10±3.7% of H2GFP+ MECs were found to 
be CD24+/CD29+ and 17±7.4% of H2BGFP+ MECs were CD24+/CD29lo, I concluded 
that most H2BGFP+ MECs were differentiated and that there is no special correlation 
between H2BGFP expression and mammary stem cell/progenitor populations.  (Averages 
and standard deviations were derived from experimental n = 4).  Tissue sections from four-  
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Figure 3- 7. Rosa26rtTA/H2BGFP Induction – Immunofluorescence. Tissues were harvested from 4 week old 
double transgenic females treated with constant doxycycline.  Direct visualization of frozen sections from a) Mammary 
gland b) Mammary gland 40x c) Brain d) Lung e) Liver f) Muscle g) Small intestine h) Pancreas i) Kidney j) Spleen k) Ovary 
l) Fallopian tube 
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week old induced Rosa26rtTA/H2BGFP female mice were immunostained for the 
mammary lineage markers CK18 and CK14 (Figure 23-9).  By immunofluorescence, no 
correlation was observed between H2BGFP expression and known mammary lineages.   
Although this level of H2BGFP induction was lower than what was originally hoped 
for at the start of a label retention experiment, it remained possible that label-retaining cells 
derived from a small percentage of total MECs could still yield a novel population with 
potentially interesting stem cell/progenitor properties.  Therefore, Rosa26rtTA/H2BGFP 
transgenic mice were removed from doxycycline treatment at four weeks post-birth for a six 
Figure 3- 8. Rosa26rtTA/H2BGFP Induction – Flow Cytometry. Mammary glands were harvested from Rosa26rtTA/ 
H2BGFP doxycycline-treated females at 4 weeks.  Flow cytometric analysis was performed on a) Wild-type MECs b) 
Rosa26rtTA/H2BGFP MECs, H2BGFP expression c) Rosa26rtTA/H2BGFP MECs, CD24/CD29 expression d) 
Rosa26rtTA/H2BGFP MECs, CD24+/CD29+ gate, H2BGFP expression e) Rosa26rtTA/H2BGFP MECs, 
CD24+/CD29lo gate, H2BGFP expression f) Rosa26rtTA/H2BGFP MECs, H2BGFP+ gate, CD24/CD29 expression 
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to eight week “chase” period, after which mammary glands were harvested and analyzed by 
flow cytometry and immunofluorescence.  After the chase period, 2.9±0.9% of all MECs 
remained H2BGFP+.  Within the CD24+/CD29+ population, 2.7±1.6% of MECs were 
2BGFP+, while only 0.6±0.4% of CD24+/CD29lo MECs retained H2BGFP label (Figure 3-
10).  (Averages and standard deviations were derived from experimental n = 5)   H2BGFP+ 
cells declined in both number and intensity over the chase period, suggesting label dilution 
through successive mitoses.  No correlation was observed between LRCs and markers of 
mammary stem cells/progenitors (Figures 3-9, 3-10).  However, given the limited number of 
verified markers of mammary stem cells and progenitors, the possibility remained that 
mammary LRCs could represent a previously undefined functional mammary epithelial 
population.  To test this hypothesis, mammary LRCs were isolated by FACS and tested by 
transplantation.   
NOD-SCID mice exhibit a mammary transplant growth defect 
Figure 3- 9. Rosa26rtTA/H2BGFP Induction and Label Retention - Immunofluorescence. Immunofluorescent 
staining of Rosa26rtTA/H2BGFP mammary glands after a) 4 weeks induction, left b) 4 weeks induction + 6 weeks chase, 
right.  Blue = DAPI, Green = GFP, Yellow = CK18, Red = CK14 
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The cleared mammary fat pad transplant is the standard in vivo assay for testing the 
stem cell function of MECs.  At three weeks of age, the mouse mammary gland has not yet 
fully penetrated the mammary fat pad.  The pubertal mammary epithelium can be surgically 
removed, and other cells or tissue pieces can be grown in the remaining fat pad without 
interference from endogenous mammary tissue.  Injected cells are sometimes mixed with 
reconstituted basement membrane (Matrigel™), which polymerizes at body temperature and 
can therefore physically stabilize the cells in the mammary gland.  In control experiments, 
single cell suspensions of mammary glands were gated for viability and against hematopoietic 
and endothelial lineages, and sorted for MEC populations with known repopulation activity.  
I injected these MECs into the cleared fat pads of syngeneic mice (Figure 3-11).  In parallel, I 
transplanted cells from the experimental populations.  This approach allowed me to control 
Figure 3- 10. Rosa26rtTA/H2BGFP Label Retention – Flow Cytometry. Doxycycline was removed from 
Rosa26rtTA/H2BGFP females four weeks post birth.  After 6 weeks of chase, mammary glands were harvested 
and analyzed for label retention. a) Total MECs from 4 weeks Rosa26rtTA/H2BGFP induction b) Total MECs 
after 6 weeks of chase, total LRCs c) LRCs within the CD24+/CD29+ population d) LRCs within the 
CD24+/CD29lo population e) Total MECs from 4 weeks Rosa26rtTA/H2BGFP induction f) Total MECsafter 6-8 
weeks chase g) CD24/CD29 expression of LRCs h) Comparison of intensity of H2BGFP+ cells before (green) 
and after (red) label retention 
42 
 
for technical variability between individual experiments.  The calculated mammary 
repopulation frequency was determined to be 1/2,600, with a 95% confidence interval of 
1/1,900 to 1/3,500, for total MECs.  The repopulation frequency for the CD24+/CD29+ 
stem cell population was 1/85, with a 95% confidence interval of 1/55 to 1/130.  These data 
fall within the range of previously published mammary repopulation data for both total 
MECs (1/1,400 - 1/4,900) and CD24+/CD29+ cells [12, 13].   
To assess the repopulation ability of label-retaining cells from the 
Rosa26rtTA/H2BGFP crosses, LRCs were isolated by flow cytometry after the chase 
period.  Because the H2BGFP transgenic line and the Rosa26rtTA mice were on different 
genetic backgrounds, these mixed background MECs were transplanted into NOD-SCID 
mice.  To assay the comparative stem cell function of label retaining cells and MECs from 
the CD24+/CD29+ compartment, limiting dilutions of label-retaining CD24+/CD29+ cells, 
label-retaining non-CD24+/CD29+ cells and CD24+/CD29+ cells that had not retained 
H2BGFP were injected into the cleared fat pads of 3 week old NOD-SCID mice (Figure 3-
Figure 3- 11. Cleared Fat Pad Transplants of Control Populations. Mammary epithelial cells were sorted and 
transplanted at limiting dilutions into the cleared mammary fat pads of syngeneic mice.  Mammary fat pads were harvested 
after 6 weeks.  Transplants were conducted as follows  a) Control clearings, no MEC injection b) Unfractionated mammary 
epithelial cells, gated against other lineages c) MECs gated from the CD24+/CD29+ stem cell compartment d) 
Differentiated MECs 
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12).  I calculated the mammary repopulating unit (MRU) frequency of each population, using 
single-hit Poisson statistical methods [104]. 
Unexpectedly, the mammary repopulation rate for these injections was extremely 
low.  The label retaining CD24+/CD29+ cells had a calculated MRU frequency of 1/7,200 
and the label retaining non-CD24+/CD29+ cells had a MRU frequency of 1/7,000.  Non-
label retaining CD24+/CD29+ MECs had an MRU frequency of 1/6,000.  As the LRC 
population was not enriched for stem cells, the non-label retaining CD24+/CD29+ cells were 
expected to have an MRU frequency comparable to what was previously published for the 
unfractionated CD24+/CD29+ compartment, 1/64 [12].  The outgrowths from these 
transplants were also observed to be significantly smaller than mammary glands grown from 
syngenic transplants (Figure 3-13). 
 There are several possible explanations for these results.  Given the cellular 
heterogeneity of the mammary gland single cell suspensions used in FACS and the broad 
tissue spectrum of Rosa26rtTA activity, it is possible that the H2BGFP+ label retaining cells  
isolated from the Rosa26rtTA/H2BGFP cross are heavily contaminated with GFP+ non-
mammary cells.  However, the repopulation activity of H2BGFP-/CD24+/CD29+ cells in  
Figure 3- 12. Rosa26rtTA/H2BGFP Label Retention - Transplant Assays. Mammary epithelial cells were sorted from 
Rosa26rtTA/H2BGFP mice after a 6-8 week chase period, and injected into cleared fat pads of NOD-SCID mice at 
limiting dilutions.   
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Figure 3- 13. Whole Mounts from Rosa26rtTA/H2BGFP label retention transplants. Mammary fat pad whole 
mounts from transplants of  a) Rosa26rtTA/H2BGFP CD24+/CD29+ LRCs into NOD-SCID fat pads b) 
Rosa26rtTA/H2BGFP non-CD24+/CD29+ LRCs, into NOD-SCID fat pads c) Rosa26rtTA/H2BGFP CD24+/CD29+ 
non-LRCs, into NOD-SCID fat pads d) 100 CD24+/CD29+ MECs into syngenic fat pads e) 1,000 unfractionated MECs 
into syngeneic fat pads 
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NOD-SCID mice was much lower than was found in injections into syngeneic fat pads, 
which suggests the problem is with the assay, not the donor cells.  As the 
Rosa26rtTA/H2BGFP MECs were derived from fully developed adult mammary glands, the  
growth defect is probably not caused by any intrinsic or genetic factors within the MECs.  It 
also is unlikely that the problem is associated with Matrigel, or any other injection-related 
reagents, as successful cleared fat pad transplants were being performed concurrently with 
these experiments.   
As this unusually low reconstitution rate occurred only when NOD-SCID mice were 
used, and all other transplants were performed by injecting MECs into syngeneic 
backgrounds, I concluded that the low reconstitution rate was the result of the NOD-SCID 
mammary fat pad environment.  Although mouse mammary tumor cells are routinely 
injected into the cleared fat pads of NOD-SCID mice, it is possible that successful 
transplants of normal MECs require an immune component lacking in NOD-SCID mice; 
for example, macrophage activity, which is required for normal mammary development, is 
impaired in NOD-SCID mice [110, 111].  Alternatively, the mammary fat pads of NOD-
SCID mice might be missing growth factors necessary to the engraftment or proliferation of 
normal mammary epithelial cells; human MECs grown in NOD-SCID mammary fat pads 
require the pre-implantation of human stromal cells for the creation of a viable environment 
[112].  NOD-SCID females are able to nurse their own pups, so this fat pad defect is either 
compensated for in NOD-SCID MECs or is critical only to mammary glands which are 
transplanted after birth.   
Given the report of successful transplants of normal MECs into NOD-SCID 
mammary fat pads [35], it is possible that the mammary fat pad defect observed in my 
experiments were not general to all NOD-SCID mice, but to the specific mice used for these 
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experiments.  NOD-SCID mice were primarily obtained from Charles River Laboratories, 
and it is possible that any mammary fat pad growth defect is caused by either the genetic 
sub-strain of the Charles River colony, or to the environmental conditions in which this 
colony was raised.  Dietary alterations have been demonstrated to affect mammary 
development during puberty [113, 114].   
This NOD-SCID problem could have been circumvented by crossing the 
Rosa26rtTA and H2BGFP transgenic strains onto the same inbred background, obviating 
the need for transplants into NOD-SCID mice.  Alternatively, other immunodeficient strains 
(e.g. Nu/Nu, RAG-1) might be able to grow transplanted, non-tumor mammary cells.  
Concurrent experiments using the MMTVrtTA transgenic mouse demonstrated H2BGFP 
expression in the mammary gland at a significantly higher level than Rosa26rtTA.  
Additionally, MMTVrtTA induced minimal H2BGFP expression outside of the mammary 
gland, reducing the risk of contamination from other H2BGFP+ cell types.  Therefore, I 
discontinued the Rosa26rtTA/H2BGFP experiments in favor of the MMTVrtTA system.   
MMTVrtTA induces H2BGFP preferentially in mammary epithelial cells 
expressing markers of stem cells and progenitors 
 The MMTVrtTA transgenic mouse was developed by Gunther et al. to express 
transgenes inducibly in the mammary gland.  When crossed with transgenic mice carrying 
tet-inducible strains, doxycycline treatment reportedly induces transgene expression in the 
mammary gland, and at low levels in the salivary gland [65].  By contrast, other MMTV- 
driven transgenes reportedly are expressed in the seminal vesicles and lymphoid cells as well 
[60, 101].  These findings suggest that the tissue-specific activity of MMTV depends on its 
insertion site and can vary significantly between transgenic lines.  In six week-old 
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MMTVrtTA/LacZ mice, 72 hours of doxycycline treatment was found to induce LacZ 
expression in the mammary gland in a dose-dependent, homogenous and completely 
penetrant fashion[65].  Because MMTVrtTA induction resulted in β-galactosidase activity in 
100% of the mammary epithelium, this strain appeared ideal for a label retention study in the 
mammary epithelium.   
 I crossed the MMTVrtTA transgenic strain with H2BGFP mice.  Because both the 
CMVrtTA and MMTVrtTA transgenic strains were on the FVB genetic background, the 
H2BGFP mice were backcrossed onto FVB, allowing syngeneic transplants of any label 
retaining cells from these crosses.  MMTVrtTA/H2BGFP breeders and pups were 
maintained constantly on doxycycline until the pups were four weeks of age.  Mammary 
glands were harvested from four week-old double transgenic MMTVrtTA/H2BGFP females 
and the induction of H2BGFP  was assessed by immunofluorescence and flow cytometry at 
the beginning of the label retention experiment (Figure 3-14, 3-15, 3-16, 3-17, 3-18).   
 Unexpectedly, H2BGFP expression was observed in only a fraction (18 ±3.1%) of 
all MECs (Figure 3-14a).  Doxycycline obtained from various sources was tested in induction 
experiments and found to evoke the same degree of H2BGFP expression (data not shown).  
To determine whether MMTVrtTA-induced H2BGFP expression correlated with specific 
MEC populations, H2BGFP+ cells were analyzed for expression of the known mammary 
stem cell/progenitor markers CD24, CD29 and CD49f.  Notably, all H2BGFP+ MECs 
stained positive for markers of either the mammary epithelial stem cell (CD24+/CD29+, 
CD24+/CD49f+) or progenitor (CD24+/CD29lo, CD24+/CD49flo) compartments (Figure 3-
14d, g).  Of the H2BGFP+ cells, 47±11% were CD24+/CD29+, 39±11% were 
CD24+/CD29lo.  Of the CD24+/CD29+ and CD24+/CD29lo MECs, 55±6.7% and 15±4.4% 
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were H2BGFP+, respectively (Figure 3-14e, f).  (Averages and standard deviations were 
derived from an n = 10.) 
By CD24/CD49f analysis, 36±7.1% were CD24+/CD49f+ and 50±1.7% were 
CD24+/CD29lo (Figure 3-14d, g).  In the CD24+/CD49f+ compartment, 46±2.6% of MECs 
were H2BGFP+, and 21±2.7% of CD24+/CD49flo MECs were H2BGFP+ (Figure 3-14h, i).  
While all H2BGFP+ subpopulations exhibited a range of H2BGFP expression levels, 
CD24+/CD29lo and CD24+/CD49flo progenitor-containing populations were found to have 
a higher range of fluorescence intensity than CD24+/CD29+ and CD24+/CD49f+ stem cell-
containing compartments.  (Averages and standard deviations were derived from an n = 4.) 
To characterize the pattern of MMTVrtTA/H2BGFP expression in situ, mammary glands 
from four week-old double transgenic, doxycycline-induced females were sectioned and 
immunostained for CK8, CK14, p63, and β1 integrin (CD29).  Consistent with the flow 
cytometry data, MMTVrtTA induced a mosaic pattern of H2BGFP expression, with a range 
of fluorescence levels.  Luminal, myoepithelial and basal/cap cell populations contained 
some H2BGFP+ MECs (Figure 3-15).  The majority of H2BGFP+ MECs were detected 
within the basal layer of the ductal tree and the cap cells of the terminal end buds.  These are 
known niches for mammary stem cells and correlate with our finding that approximately half 
of all CD24+/CD29+ cells were H2BGFP+ [12].  Fewer H2BGFP+ cells were detected within 
the luminal layer, which also is consistent with ~15% of the cells within the CD24+/CD29lo 
population being H2BGFP+. 
MMTVrtTA/H2BGFP mammary glands also were immunostained to detect 
expression of steroid hormone receptors, which is associated with differentiated MEC 
populations [12, 13, 40].  MMTVrtTA/H2BGFP induced mammary glands were sectioned 
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Figure 3- 14. . Flow cytometric analysis of MMTVrtTA/H2BGFP induction.  Representative FACS plots from 
MMTVrtTA/H2BGFP induction mammary glands.  Analysis of total MEC population by expression of a) H2BGFP b) 
CD24/CD29 c) CD24/CD49f.  H2BGFP expression within the e) CD24+/CD29+ gate f) CD24+/CD29lo+ gate h) 
CD24+/CD49f+ gate i) CD24+/CD49f lo gate.  Stem cell/progenitor marker expression within the H2BGFP+ 
population d) CD24/CD29 g) CD24/CD49f   
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and immunostained for ER (Figure 3-16), PR (Figure 3-17) and glucocorticoid receptor (GR) 
(Figure 3-18), which activates the MMTV promoter and plays a role in mammary 
proliferation during pregnancy.  In these pubertal mice, the majority of cells in the ducts and 
TEBs were found to be ER+ and GR+.  H2BGFP was co-expressed with ER and GR in 
some of these cells.  Interestingly, H2BGFP+ cells were consistently negative for PR staining 
(Figure 3-17).   
MMTVrtTA label retention in the mammary gland 
My discovery that MMTVrtTA induces H2BGFP expression principally in the 
mammary stem cell and progenitor compartments raised the possibility that LRCs found 
using the MMTVrtTA/H2BGFP system could represent novel subpopulations of mammary 
stem cells and/or progenitors and provide new details about the mammary stem cell 
hierarchy.  Therefore, I conducted histone label retention studies in the mouse mammary 
gland using the MMTVrtTA/H2BGFP system.   
MMTVrtTA/H2BGFP females were treated constantly with doxycycline until four 
weeks post-birth, at the beginning of the chase period.  Experimental mice were kept from 
doxycycline for a six to eight week chase period.  At the end of the chase period, mammary 
glands were harvested from experimental mice, and purified by FACS (Figure 3-19).  
H2BGFP+ MECs post-chase were reduced in both number and intensity (Figure 3-19 b, h).  
After this chase period, 2±0.8% of all MECs were found to be H2BGFP+.  Of the 
CD24+/CD29+ cells analyzed, 4.8±1.9% were H2BGFP+ LRCs, while 1.4±1.0% of 
CD24+/CD29lo cells were LRCs.  This is consistent with an approximately ten-fold 
reduction of detectable H2BGFP+ cells across the entire mammary gland.  Among the 
LRCs, 46.6±14.7% were found to be CD24+/CD29+, which corresponded with pre-chase   
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Figure 3- 15. Analysis of Lineage Marker Expression in MMTVrtTA induction of H2BGFP expression in the 
mammary glands. Representative immunostainings of mammary glands harvested from 4 week old double transgenic 
females treated with doxycycline, sectioned and stained with a) CK8 b) CK14 c) p63 d) β1 integrin. Photographs depict 
normal ducts (left) and terminal end buds (right).   
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Figure 3- 16. Immunostaining of MMTVrtTA/H2BGFP Mammary Glands for Estrogen Receptor. Mammary 
glands from four week old doxycycline-treated females were sectioned and stained for estrogen receptor a) Mammary duct 
b) Terminal end bud 
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Figure 3- 17. Immunostaining of MMTVrtTA/H2BGFP Mammary Glands for Progesterone Receptor. Mammary 
glands from four week old doxycycline-treated females were sectioned and stained for progesterone receptor a) Mammary 
duct b) Terminal end bud 
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Figure 3- 18. Immunostaining of MMTVrtTA/H2BGFP Mammary Glands for Glucocorticoid Receptor.  Mammary 
glands from four week old doxycycline-treated females were sectioned and stained for glucocorticoid receptor. a) Mammary 
duct b) Terminal end bud 
55 
 
analysis of H2BGFP+ MECs.  However, only 25.7±16.8% were CD24+/CD29lo, which is  
lower than the pre-chase proportion; this can be accounted for by considering the greater 
[proliferation activity and label dilution of CD24+/CD29lo progenitors (Figure 3-19g, 3-14d).  
(Averages and standard deviations were derived from an n = 12.)  
Label retention within the CD24+/CD29+ stem cell compartment was expected, but 
the sizeable fraction of CD24+/CD29lo LRCs required some consideration of mammary 
gland dynamics.  If the pubertal mammary gland follows the classical stem cell hierarchy, 
with stem cells generating progenitors and progenitors giving rise to large numbers of 
differentiated cells, active progenitors during puberty would not be expected to indefinitely 
retain an H2BGFP label.  However, H2BGFP+/CD24+/CD29lo MECs exhibited a higher 
range of fluorescence at 4 weeks than H2BGFP+/CD24+/CD29+ MECs.  Therefore, it is
 
Figure 3- 19. MMTVrtTA/H2BGFP Label Retention. Doxycycline was removed from MMTVrtTA/H2BGFP females 
four weeks post birth.  After 6-8 weeks of chase, mammary glands were harvested and analyzed for label retention. a) Total 
MECs from 4 weeks MMTVrtTA/H2BGFP induction b) Total MECs  after 6-8 weeks of chase, total LRCs c) LRCs within 
the CD24+/CD29+ population d) LRCs within the CD24+/CD29lo population e) Total MECs from 4 weeks 
MMTVrtTA/H2BGFP induction f) Total MECs after 6-8 weeks chase g) CD24/CD29 expression of LRCs h) Comparison 
of H2BGFP intensity before (green) and after (red) label retention 
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possible that H2BGFP+/CD24+/CD29lo cells had not gone through enough mitoses by the 
end of puberty to dilute H2BGFP below the threshold of detection in progenitors.  
Alternatively, the label-retaining H2BGFP+/CD24+/CD29lo MECs might have been or 
become mitotically quiescent during puberty, suggesting a role for these cells other than that 
of active progenitor during puberty.  Therefore, H2BGFP+/CD24+/CD29lo LRCs could 
represent terminally differentiated cells, which maintained H2BGFP label because they had 
completed all of their allotted mitoses, or they could be label-retaining progenitor cells, 
which function at later stages of mammary development, such as estrus or pregnancy.  
Finally, it is possible that these CD24+/CD29lo LRCs are progenitors that retain label 
through asymmetric histone distribution, suggesting a novel mechanism for histone 
segregation in mammary stem cells and/or progenitors.   
To assess the functional significance of the H2BGFP LRCs, label retaining and non-
label retaining MECs from both the CD24+/CD29+ and CD24+/CD29lo compartments were 
sorted and transplanted into the cleared fat pads of syngenic mice.  All populations were 
double-sorted with doublet discrimination to ensure purity, and were recounted by 
hemacytometer post-sort to obtain an accurate cell count.  Recipient mice were maintained 
on doxycycline to continue transgene induction.  Mammary fat pads were harvested after a 
six week growth period and stained with carmine alum to visualize mammary outgrowths.  
The resulting mammary glands were scored, and the mammary repopulating unit (MRU) 
frequency of each sorted population was calculated using single-hit Poisson statistics [104]  
(Figure 3-20). 
Within the CD24+/CD29+ population, the LRCs were found to have a calculated 
MRU frequency of 1/160, with a 95% confidence interval of 1/110 to 1/240, and non-LRCs 
had an MRU frequency of 1/270, with a confidence interval of 1/160 to 1/460.  Given the 
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overlapping confidence intervals, this 1.7-fold difference in mammary repopulation ability is 
unlikely to represent a significant functional difference between LRCs and non-LRCs in the 
CD24+/CD29+ compartment.  (Averages and standard deviations were obtained from 
experimental n= 12) 
Within the CD24+/CD29lo population, the LRCs had an MRU frequency of 1/520, 
compared with the 1/1,900 frequency of non-LRC CD24+/CD29lo MECs.  These results 
were unexpected, as CD24+/CD29lo cells were initially reported to have no in vivo 
repopulation ability[12].  In spite of various technical precautions, the small number of 
mammary outgrowths found in these CD24+/CD29lo injections could have been the result 
Figure 3- 20. MMTVrtTA/H2BGFP Label Retaining Cells - Repopulation Assays. Populations were sorted from 
MMTVrtTA/H2BGFP mammary glands after 6-8 weeks of chase.  Sorted MECs were transplanted into cleared 
fat pads, grown for 6 weeks, harvested, stained with carmine alum and scored.  Mammary repopulation unit 
frequencies were calculated using single-hit Poisson statistics, with 95% confidence intervals.   
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of contamination.  However, because LRCs represented 1.4% of all CD24+/CD29lo MECs, 
it also was possible that I had enriched for a previously unknown sub-population with in vivo 
repopulating activity that had gone undetected in limiting dilution injections of the whole 
CD24+/CD29lo population.    
Induction vs. Label Retention in the MMTVrtTA/H2BGFP model 
Based on the above data, it was possible that I had isolated a unique mammary 
progenitor through H2BGFP label retention in the CD24+/CD29lo population.  However, 
the induction of MMTVrtTA/H2BGFP in subpopulations of the CD24+/CD29+ and 
CD24+/CD29lo compartments meant that it was possible that any enrichment in stem 
cell/progenitor activity might be due to H2BGFP induction, not H2BGFP label retention.  
Although MMTV promoter activity is known to be dependent on its location within the 
genome, the MMTV promoter might be turned on preferentially in mammary stem cells and 
progenitors; from the perspective of viral evolution, stem cells and progenitors are able to 
effectively propagate the viral genome through their numerous progeny, making stem 
cell/progenitor-specific activity a useful survival strategy.   
To determine whether H2BGFP label retention or induction was responsible for the 
observed mammary repopulation phenotype of LRCs, CD24+/CD29+ and CD24+/CD29lo 
populations with and without H2BGFP expression were isolated from doxycycline-treated 
MMTVrtTA/H2BGFP females four weeks post-birth, without any chase.  MEC populations 
were purified by FACS and subjected to limiting dilution transplantation analysis (Figure 3-
20).  H2BGFP+/CD24+/CD29+ MECs had an MRU frequency of 1/80, with a 95% 
confidence interval of 1/60 to 1/120 and H2BGFP-/CD24+/CD29+ MECs had an MRU 
frequency of 1/100, with a confidence interval of 1/80 to 1/150.  This minimal difference 
59 
 
demonstrates that in primary transplants, there is no difference in the repopulation ability of 
H2BGFP+ and H2BGFP- MECs in the CD24+/CD29+ compartment of induced 
MMTVrtTA/H2BGFP MECs.  Surprisingly, induced H2BGFP+/CD24+/CD29lo MECs had 
a calculated repopulation rate of 1/710, with a confidence interval of 1/370 to 1/1,400.  
Many of these mammary outgrowths were diminutive when compared to the glands 
produced by the CD24+/CD29+ populations (Figure 3-22).  By contrast, H2BGFP-
/CD24+/CD29lo cells did not produce any mammary outgrowths, which is consistent with 
the lack of reported repopulating activity of bulk CD24+/CD29lo cells [12].  Therefore, the 
apparent improvement in mammary repopulating ability in H2BGFP+/CD24+/CD29lo cells 
seen in label retention experiments was not actually due to enrichment by label retention, but 
Figure 3- 21. MMTVrtTA/H2BGFP Induction - Repopulation Assays. Populations were sorted from mammary 
glands of doxycycline-treated MMTVrtTA/H2BGFP females four weeks post-birth.  Sorted MECs were transplanted into 
cleared fat pads, grown for 6 weeks, harvested, stained with carmine alum and scored.  Mammary repopulation unit 
frequencies, with 95% confidence intervals, were calculated using single-hit Poisson statistics.   
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rather reflected differential properties of the H2BGFP+/CD24+/CD29lo and H2BGFP-
/CD24+/CD29lo marked by MMTVrtTA/H2BGFP induction.   
H2BGFP+/CD24+/CD29lo MECs represent only 15% of the CD24+/CD29lo 
compartment, giving the repopulating cell a frequency of 1/4,700 within the CD24+/CD29lo 
MECs.  This low frequency might mean that the H2BGFP+/CD24+/CD29lo population 
contains a population of previously undetected mammary stem cells or progenitors.  It also 
is possible that the mammary structures produced by this population were previously 
overlooked because of their size.  In either case, the H2BGFP+/CD24+/CD29lo population 
merited further examination, which is the topic of Chapter 3.   
Discussion & Future Directions 
Figure 3- 22. H2BGFP+/CD24+/CD29lo Induction – Whole Mounts. Whole mount carmine alum stainings of 
mammary fat pads from injections of the H2BGFP+./CD24+/CD29lo population.  Circles were drawn around particularly 
difficult-to-detect mammary outgrowths.  All outgrowths were verified by sectioning and immunostaining 
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 Through the use of the tetracycline-inducible H2BGFP transgenic mouse model, I 
have investigated the possibility of identifying and isolating novel mammary stem cells and 
progenitors through histone label retention.  Previous DNA label retention studies in the 
mammary gland have used pubertal proliferation, or a hormone-enhanced variant of the 
same, for label dilution studies [29, 86].  These studies identified LRCs with potentially 
interesting properties, but direct isolation of LRCs for growth assays was technically 
unfeasible.   
My H2BGFP label retention studies were directed at the isolation and 
characterization of histone label retaining cells in the mammary gland.  H2BGFP induction 
requires expression of a tetracycline transactivator, which, for such studies, ideally would be 
active in all mammary epithelial cells, and absent from any potentially contaminating 
lineages, such as fibroblasts, endothelial cells and circulating hematopoietic cells.  Label 
retention assays, which require the isolation and characterization of a small population, are 
sensitive to contamination, particularly in heterogeneous tissues such as the mammary gland.  
I found that the CMVrtTA transgenic line did not express H2BGFP in the mammary gland.  
The MMTVtTA model was found to induce H2BGFP expression in ~6% of MECs, but was 
determined to be unsuitable for label retention due to a combination of low expression in 
the mammary gland and higher levels of H2BGFP expression in the lymphoid system.   
Rosa26rtTA induced H2BGFP expression in 9% of MECs, and numerous other 
tissues; withdrawal of doxycycline in early puberty resulted in H2BGFP label dilution (Figure 
3-10).  However, I found that the calculated MRU frequency of CD24+/CD29+ MECs 
transplanted into NOD-SCID fat pads was almost 100x lower than expected (Figure 3-12).  
Because control transplants of MECs into syngenic mammary fat pads produced mammary 
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outgrowths at the expected frequency (Figure 3-11), I concluded that NOD-SCID mammary 
fat pads lack a critical component required for growth of exogenous MECs.   
 The MMTVrtTA/H2BGFP transgenic model resulted in H2BGFP expression in 
18% of all MECs, as detected by flow cytometry.  Unexpectedly, I discovered that 
MMTVrtTA induced H2BGFP expression principally within MECs expressing markers for 
mammary stem cells and progenitors.  These findings contrasted with data from Gunther et 
al. who found MMTVrtTA activity in 100% of the mammary epithelium [65].  The most 
likely explanation for this discrepancy is that MMTVrtTA activity was monitored by 
expression of LacZ; the β-galactosidase assay is more sensitive than fluorescence detection.   
Based on the lack of association between H2BGFP expression and mammary stem 
cell/progenitor markers in the Rosa26rtTA/H2BGFP model, I concluded that the 
unexpected expression pattern exhibited by the MMTVrtTA/H2BGFP model was unlikely 
to be caused by the H2BGFP transgene.  Given that I detected MMTVrtTA induction 
exclusively in mammary stem cell and progenitor populations, it is possible that H2BGFP 
protein exists in all MECs, through inheritance from an H2BGFP-expressing progenitor, but 
at a level below the threshold of fluorescence detection.  Alternatively, H2BGFP protein 
could be less stable than LacZ in differentiated cells.  Nevertheless, my finding of mosaic 
MMTVrtTA activity in this transgenic line suggests that other studies that have utilized these 
mice might require reexamination, particularly if the conclusions drawn from these studies 
were dependent on homogenous transgene induction across the entire mammary epithelium.  
For example, studies where this MMTVrtTA transgene was used to induce tumorigenesis 
might be subject to different interpretation if these tumors arose exclusively from stem cell 
and progenitor populations.   
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The MMTVrtTA/H2BGFP induction data also differed from the expression pattern 
observed in the Rosa26rtTA/H2BGFP model, which found no correlation between 
H2BGFP expression and mammary lineage markers by either flow cytometry or 
immunostaining, even after label retention.  Although the MMTVtTA/H2BGFP might be 
expected to have an expression pattern similar to that of MMTVrtTA/H2BGFP, 
MMTVtTA gene induction was found to be significantly lower in the mammary gland, and 
higher in the lymphoid system than in the MMTVrtTA system.  This is most likely to be the 
result of different transgene locations, although it is possible that the different expression 
patterns are due to differences between the reverse tetracycline transactivator and 
tetracycline transactivator.  The location of the MMTV promoter on the nucleosome has 
been previously reported to strongly affect MMTV promoter activity [58].  Unfortunately, at 
the time I was conducting experiments using the MMTVtTA mice, markers for mouse 
mammary stem cells and progenitors had not been published; therefore, I have no data to 
directly compare MMTVtTA induction with the MMTVrtTA induction in mammary stem 
cell/progenitor compartments.  Although this remarkable pattern of MMTVrtTA induction 
of H2BGFP is most likely due to MMTVrtTA activity, I can draw no conclusion about 
whether the MMTV promoter itself, the transgene’s location in the genome, or both, are 
directly responsible for the pattern of MMTVrtTA activity in the mammary epithelial stem 
cell/progenitor compartments.   
The observed expression pattern in MMTVrtTA/H2BGFP MECs raised the 
possibility that any increased stem cell/progenitor activity in LRC populations was a product 
of H2BGFP label retention or induction.  Therefore, I performed limiting dilution 
transplants of H2BGFP+ and H2BGFP- MEC populations from mammary glands that had 
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been induced but not chased, as well as glands from label retention experiments.  I observed 
no improvement in repopulation ability due to label retention.   
Based on these experiments, I am unable to draw any conclusions about histone 
label retaining cells in the mammary gland.  It remains possible that histone label retention 
assays could yield previously unknown mammary epithelial cell types.  At present, the 
H2BGFP label retention system is limited by the available reagents for inducing H2BGFP 
expression in specific tissues.   
Interestingly, I found that H2BGFP+/CD24+/CD29lo MECs were able to produce 
mammary outgrowths while H2BGFP-/CD24+/CD29lo cells were unable to do so (Figure 3-
21, 3-22).  I concluded that MMTVrtTA/H2BGFP induction in the mammary gland labels a 
subpopulation within the CD24+/CD29lo compartment which has different properties from 
the bulk of the CD24+/CD29lo cells, and might represent a novel multipotent progenitor 
with in vivo reconstitution ability.  Characterization of the MEC populations labeled by 
MMTVrtTA/H2BGFP induction is covered in the next chapter of this thesis.   
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Chapter 4 Evidence for a novel 
multipotent mammary progenitor with 
pregnancy-specific activity 
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Introduction 
 Studies of mammary gland development have contributed to our understanding of 
the mammary stem cell hierarchy, which establishes the mammary architecture during 
puberty and gives rise to milk-producing alveoli during pregnancy.  The existence of 
mammary stem cells was established by demonstrating that a single mammary epithelial cell 
can give rise to a fully functional mammary gland [12, 13, 25].  Lineage tracing and 
differentiation studies have provided evidence for lineage-specific mammary progentiors [12, 
13, 38].  Although markers for mammary stem cells and progenitors have been identified, 
these populations have not been isolated to purity and our understanding of how they 
function in different stages of mammary development remains incomplete.   
 In the previous chapter of this thesis, I described experiments in which I attempted 
to isolate and characterize mammary stem cells and progenitors through isolation of cells 
that retain fluorescently tagged histone 2B after a chase period.  I unexpectedly discovered 
that MMTVrtTA induced H2BGFP expression principally in the CD24+/CD29+ and 
CD24+/CD29lo populations, which contain stem cells and progenitors, respectively.  
Furthermore, I found that the H2BGFP+/CD24+/CD29lo population was able to give rise to 
multi-lineage mammary outgrowths in vivo.  The CD24+/CD29lo population was originally 
reported to have no in vivo repopulation ability; however, while my work was in progress, 
other groups also reported that CD24+/CD29lo MECs could give rise to limited mammary 
outgrowths [35, 36].  Additionally, CD24+/CD49flo MECs, which were also reported to have 
no in vivo potential, were found to give rise to mammary outgrowths able to form alveoli in 
pregnant recipients [35].  These studies suggested the existence of multipotent mammary 
progenitors in these compartments.   
67 
 
To determine whether MMTVrtTA/H2BGFP expression labels novel mammary stem cells 
or progenitors, I have assayed these MMTVrtTA/H2BGFP MEC populations for in vivo and 
in vitro growth ability and studied their gene expression profiles.  This chapter reports 
evidence for a novel pregnancy-activated multipotent progenitor within the mouse 
mammary gland, and describes its functional properties.   
Results 
MMTVrtTA/H2BGFP expression in the CD24+/CD29+ compartment does 
not label long term mammary stem cells 
 In the hematopoietic system, stem cells have been sub-categorized based on their 
ability to reconstitute multi-lineage tissues over numerous serial transplants.  Hematopoietic 
stem cells capable of sustaining developmental proliferation indefinitely are referred to as 
long-term stem cells, while stem cells that are only able to regenerate for only a few rounds 
of serial transplantation are known as short-term stem cells[115].  Analogous populations 
may exist in the mammary gland, but have not yet been positively identified.   
 Previous transplant experiments comparing MEC populations from mammary 
glands of induced MMTVrtTA/H2BGFP mice demonstrated that 
H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+ MECs were functionally 
indistinguishable (Figure 3-21).  Both populations repopulated the mammary gland at similar 
frequencies, which were consistent with previously published in vivo transplant frequencies of 
the unfractionated CD24+/CD29+ cells [12].  However, these assays did not address the 
long-term repopulation potential of these populations, as defined by the ability of these cells 
to serially transplant over many generations.   
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 To test the long-term repopulating activity of MMTVrtTA/H2BGFP MECs, each of 
the four populations was sorted from the mammary glands of four week-old 
MMTVrtTA/H2BGFP females by flow cytometry.  In each experiment, each MEC 
population was injected into 10 cleared fat pads of syngeneic mice in 500-cell aliquots.  
Recipient mice were treated with doxycycline to promote H2BGFP expression.  After six 
weeks, transplanted fat pads were harvested and pooled according to transplanted cell type, 
analyzed by flow cytometry and re-transplanted. MMTVrtTA/H2BGFP populations were 
serially transplanted to secondary transplants in two experiments, and to a tertiary transplant 
in one experiment.  H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+ MECs gave 
rise to serially transplantable mammary glands (Figure 4-1c, d).  The transplanted 
CD24+/CD29+ gave rise to smaller percentages of CD24+/CD29+ and CD24+/CD29lo 
MECs than was found in the control glands; since serial transplants took place at six-week 
intervals, and mouse mammary fat pads are usually filled around eight to ten weeks post-
birth, these percentages probably reflect incompletely filled mammary fat pads and higher 
percentages of non-epithelial cells.  Surprisingly, only H2BGFP+/CD24+/CD29+ cells gave 
rise to mammary glands expressing H2BGFP.  This result suggested that H2BGFP 
expression was permanently turned off in the H2BGFP-/CD24+/CD29+ populations.  To 
eliminate the possibility that the apparent H2BGFP-/CD24+/CD29+ outgrowths were 
actually the product of endogenous MECs from incompletely cleared mammary fat pads, 
genomic DNA was harvested from transplant mammary glands after tertiary transplants and 
tested by PCR for MMTVrtTA and H2BGFP transgenes.  Both transgenes were present in 
H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+-derived glands, demonstrating 
their transgenic origin.  Therefore, both CD24+/CD29+ populations are capable of long 
term in vivo stem cell activity, but H2BGFP expression in the CD24+/CD29+ population is  
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Figure 4- 1. Serial Transplants Analysis of MMTVrtTA/H2BGFP Populations. Representative flow cytomtetry 
plots of serial transplants.   MMTVrtTA/H2BGFP MEC populations were sorted and transplanted at six week intervals; 
two experiments were carried out to secondary transplants, and one experiment was carried to tertiary transplant.  Serially 
transplanted glands were analyzed by flow cytometry for expression of CD24/CD29 (left) and H2BGFP (right).  Analysis 
of a) WT MECs b) empty mammary fat pads c) H2BGFP+/CD24+/CD29+ d) H2BGFP-/CD24+/CD29+ e) 
H2BGFP+/CD24+/CD29lo f) H2BGFP-/CD24+/CD29lo 
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epigenetically inherited and does not distinguish functionally different populations of 
CD24+/CD29+ cells.   
Notably, the H2BGFP+/CD24+/CD29lo population was unable to serially transplant, 
suggesting a progenitor origin for H2BGFP+/CD24+/CD29lo-derived mammary 
outgrowths.   
H2BGFP+/CD24+/CD29lo contain a population of pregnancy-activated 
multipotent mammary progenitors 
 In Chapter 3, I showed that H2BGFP+/CD24+/CD29lo cell transplants were able to 
form small mammary glandular structures (Figure 3-21, 3-22).  Although diminutive, these 
structures contained both luminal and myoepithelial/basal lineages and were able to produce 
milk, but had no serial transplantation ability (Figure 4-1).  By contrast, H2BGFP-
/CD24+/CD29lo MECs were unable to produce any mammary outgrowths in vivo, suggesting 
different functions for H2BGFP+ and H2BGFP- cells within the CD24+/CD29lo 
compartment.  Therefore, MMTVrtTA induction of H2BGFP labels a CD24+/CD29lo sub-
population containing a previously uncharacterized multipotent mammary progenitor with in 
vivo repopulation potential.   
 In the transplant experiments reported in Chapter 2, some transplant recipient mice 
were maintained as virgins and others were mated post- transplant to induce pregnancy and 
increase the size and visibility of the mammary outgrowths.  To determine whether 
pregnancy affects the repopulation rate of MMTVrtTA/H2BGFFP populations, the limiting 
dilution data from virgin and pregnant mice were reanalyzed (Figure 4-2).  Mammary 
outgrowths from these experiments were also scored for their size (Figure 4-3, Figure 4-4, 
Figure 3-22).  The mammary repopulation abilities of the H2BGFP+/CD24+/CD29+ and 
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H2BGFP-/CD24+/CD29+ populations were similar in virgin and pregnant recipients (Figure 
4-2a, b, e, f).  Based on these data, I conclude that MMTVrtTA/H2BGFP expression in the 
CD24+/CD29+ compartment does not label MECs with different repopulating activity 
during pregnancy.   
 By contrast, the repopulating activity of H2BGFP+/CD24+/CD29lo MECs was 
nearly five-fold higher in pregnant mice compared to virgins.  The functional MRU 
frequency was 1/350 in pregnant mice, compared to 1/1,600 in virgins (Figure 4-2c, g).  As 
described in Chapter 2, outgrowths from H2BGFP+/CD24+/CD29lo MECs were smaller 
than glands derived from CD24+/CD29+ populations (Figures 3-22, 4-4, 4-5, 4-6), but still 
contained all mammary lineages and were able to produce milk (Figure 4-7).  H2BGFP-
/CD24+/CD29lo MECs were unable to produce mammary outgrowths in either virgin or 
pregnant mice (Figure 4-2d, h). 
To directly address whether H2BGFP+/CD24+/CD29lo MECs selectively expand 
during pregnancy, I performed a controlled, separate series of cleared mammary fat pad 
transplants (n=3), focusing specifically on the H2BGFP+/CD24+/CD29lo population.  Half 
of the mice injected with H2BGFP+/CD24+/CD29lo MECs were systematically made 
pregnant post-transplant for a direct comparison of H2BGFP+/CD24+/CD29lo 
repopulation ability in virgin vs. pregnant mice (Figure 4-6).  In these experiments, the 
calculated MRU frequency was 1/3,800 in virgin mice and 1/280 in pregnant mice.  These 
data indicated that MMTVrtTA/H2BGFP expression in the CD24+/CD29lo compartment 
labels a population containing multi-potent progenitors that exhibit proliferative activity 
preferentially during pregnancy.  
Shackleton et al. demonstrated that the CD24+/CD29+ and CD24+/CD29lo MEC 
populations could give rise to different structures when grown on a commercially available    
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Figure 4- 2. MMTVrtTA/H2BGFP Populations in Virgin Vs. Pregnancy. Limiting dilution transplants in virgin 
recipients (a-d) and pregnant recipients (e-h) of MMTVrtTA/H2BGFP populations a,e) H2BGFP+/CD24+/CD29+ b,f) 
H2BGFP-/CD24+/CD29+ c,g) H2BGFP+/CD24+/CD29lo d,h) H2GFP-/CD24+/CD29lo 
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Figure 4- 3. Mammary Outgrowth Size Scoring. Transplanted mammary fat pads were fixed, stained for carmine alum 
and scocred for size as follows.   
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Figure 4- 4. Mammary Outgrowth Size Scoring of MMTVrtTA/H2BGFP Population Transplants. Outgrowths 
from MMTVrtTA/H2BGFP induction transplants were scored for size based on ability to fill the fat pad (see Figure 3-5) in 
virgin recipients (a-d) and pregnant recipients (e-h) of MMTVrtTA/H2BGFP populations a,e) 
H2BGFP+/CD24+/CD29+ b,f) H2BGFP-/CD24+/CD29+ c,g) H2BGFP+/CD24+/CD29lo d,h) H2GFP-
/CD24+/CD29lo 
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reconstituted basement membrane gel, Matrigel™.  CD24+/CD29+ MECs gave rise to 
bilayer acinar structures, filled aciniar structures and tubular growths, while CD24+/CD29lo 
MECs gave rise to single-layer acini which were consistently hollow.  These Matrigel growth 
phenotypes are believed to be reflective of the stem/progenitor fate of these MEC 
populations.  To test the 3D growth of MMTVrtTA/H2BGFP populations, MECs were 
sorted and grown on Matrigel [12, 13].  H2BGFP+/CD24+/CD29+ and H2BGFP-
/CD24+/CD29+ MECs produced 11±5 and 13±3 acini per 1,000 cells cultured, respectively.  
Within the CD24+/CD29lo population, H2BGFP+ MECs gave rise to 100±11 and H2BGFP-
/CD24+/CD29lo MEC gave rise to 126±17 acini per 1,000 cells cultured.  Therefore, no 
differences in 3D acini growth were detected in H2BGFP+ and H2BGFP- subpopulations of   
Figure 4- 5. H2BGFP+/CD24+/CD29lo Transplants - Virgin vs. Pregnancy. H2BGFP+/CD24+/CD29lo MECs 
were sorted and transplanted in limiting dilutions.  Mammary glands were scored for outgrowths (a, b) and size (c, d) in 
virgins (a, c) and pregnant mice (b, d)  
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Figure 4- 6. Mammary Outgrowth from H2BGFP+/CD24+/CD29lo MECs. Transplanted fat pads were harvested, 
fixed and visualized by a) whole mounting, followed by sectioning and staining for b) GFP and β1 integrin (10x) c) CK8, 
GFP and p63 (60x) d) CK14, GFP and β1 integrin (60x) e) DAPI, GFP and milk 
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Figure 4- 7. H2BGFP+/CD24+/CD29lo Transplants – Second Set, Whole Mounts. Mammary fat pads injected with 
limiting dilutions of H2BGFP+/CD24+/CD29lo MECs were harvested, fixed and stained with carmine alum.  Mice were 
either maintained as virgins (lower right fat pad) or made pregnant (all other whole mounts). 
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either CD24+/CD29+ or CD24+/CD29lo MECs.  
Gene expression analysis supports biologically distinct roles for 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations 
 The above data provides evidence that H2BGFP+ CD24+/CD29lo MECs contain a 
subpopulation of pregnancy-activated multipotent progenitors.  Although the in vivo data was 
striking, it shed little light on the biochemical or molecular mechanisms of  these 
progenitors.   To further characterize the MMTVrtTA/H2BGFP MEC populations, RNA 
was isolated from each of the four MMTVrtTA/H2BGFP populations sorted from four 
week old double transgenic females and analyzed for differences in gene expression on the 
Illumina Mouse Microarray platform.  Unsupervised clustering of the data sets segregated 
the samples into the original FACS-sorted populations, as predicted by H2BGFP expression 
and functional differences.  Because I was unable to find any functional difference between 
the CD24+/CD29+ populations in primary transplants in virgin and pregnant mice, serial 
transplants and 3D in vitro growth assays, this gene expression segregation suggests that there 
may be a difference between the H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+ 
populations which I have been unable to detect.   
This analysis was focused on gene expression data from the CD24+/CD29lo 
populations.  Comparison of the gene expression levels of the H2BGFP+/CD24+/CD29lo 
and H2BGFP-/CD24+/CD29lo populations revealed that 257 probes showed statistically 
significant differences in expression between the H2BGFP+  and H2BGFP- populations of 
the CD24+/CD29lo compartments, based on the t-test p-value threshold of p<0.05.  
Fourteen of these probes, representing eleven genes, were associated with mammary gland 
development and differentiation as defined by the Gene Ontology database.  Each of the 
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mammary-related transcripts, except for mucin 1 (Muc1), were expressed at much lower 
levels in the H2BGFP+/CD24+/CD29lo population (Figure 4-8).  These included well-
documented mediators of mammary gland development, such as estrogen receptor 1, 
fibroblast growth factor receptor 2, prolactin receptor, and amphiregulin.  To validate the 
microarray data, mRNA was harvested from sorted H2BGFP+/CD24+/CD29lo and 
H2BGFP-/CD24+/CD29lo MECs from four week old double transgenic mice and 
analyzed by qPCR to determine the expression levels of genes of interest (Figure 4-9).  The 
qPCR assays confirmed the microarray data for nine of the eleven mammary development 
genes: amphiregulin (AREG), caveolin 1 (Cav1), estrogen receptor 1 (Esr1), fibroblast 
growth factor receptor 2 (FGFR2), stem cell antigen 1 (Ly6a/Sca-1), mucin 1 (Muc1), 
prolactin receptor (PRLR), roundabout homolog 1 (Robo1) and wingless-type MMTV 
integration site family, member 5A (Wnt5a).   
 To compare the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo 
populations with known mammary epithelial subtypes, data from this microarray was 
Figure 4- 8. Microarray Data for Mammary Development and Differentiation Genes. 257 probes were found to have 
statistically significant differences between H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo.  The 14 probes 
displayed above are associated with mammary development and differentiation, according to the Gene Ontology database.   
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analyzed with previously reported data from mammary stem cells (CD24+/CD29+), luminal 
progenitors (CD24+/CD29lo/CD61+) and mature luminal MECs (CD24+/CD29lo/CD61-), 
focusing on the differentially expressed genes in H2BGFP+/CD24+/CD29lo and H2BGFP-
/CD24+/CD29lo MECs [116] (Figure 4-10).  Transcripts for these genes were significantly 
enriched (p = 2.8x10-35) in genes that distinguished between the CD24+/CD29+, 
CD24+/CD29lo/CD61+ and CD24+/CD29lo/CD61+  subpopulations (p<0.05).  This result 
Figure 4- 9. Relative Fold Difference of Mammary Development and Differentiation Genes Identified by 
Microarray. Relative fold difference between transcripts in H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo 
cells.  Results are displayed in a linear plot (top) and a log plot (bottom). 
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was expected since CD24 and CD29 were used in the isolation of both populations.  
However, transcripts expressed at higher levels in H2BGFP+/CD24+/CD29lo are 3.6-fold 
enriched (p=2.5x10-16) in genes which were also expressed highly in the 
CD24+/CD29lo/CD61+  MECs, lower levels in CD24+/CD29lo/CD61-  mature cells and 
lowest levels in the CD24+/CD29+ stem cell compartment.  By contrast, the genes which 
were expressed at low levels in the H2BGFP+/CD24+/CD29lo population were enriched 
(p=1.4x10-20) in genes which also expressed at the lowest levels in CD24+/CD29+ MECs and 
the highest in the CD24+/CD29lo/CD61-   mature luminal population.  These data provide 
evidence that H2BGFP+/CD24+/CD29lo cells share characteristics with both mammary 
stem cells and luminal-limited progenitors, a phenotype which could be expected in a 
multipotent progenitor.  To further characterize the properties of MMTVrtT/H2BGFP 
MEC populations, the four populations were isolated by FACS, cytospun onto slides and 
immunostained for various mammary lineage markers (Figure 4-11).  The immunostaining of 
β1 integrin was higher in both CD24+/CD29+ populations, confirming the flow cytometry 
data.  CD24+/CD29+ populations were found to express higher levels of p63 and CK14 and 
CD24+/CD29lo populations were found to express more CK8.  These data match previous 
observations on the unfractionated CD24+/CD29+ and CD24+/CD29lo populations [40].  
Interestingly, the cytospin immunostainings confirmed the microarray and qPCR data that 
H2BGFP-/CD24+/CD29lo cells express higher levels of AREG.  H2BGFP-/CD24+/CD29lo 
cells also expressed higher levels of PR and GR, which suggests a more differentiated fate 
for these cells.  It is interesting to note that higher levels of PR and GR in an H2BGFP- 
population supports the hypothesis that the location of the MMTVrtTA transgene, not  
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Figure 4- 10. Comparison of MMTVrtTA/H2BGFP Microarray Data with Visvader Microarray. Expression of 
genes which were differentially regulated between H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo (left 
columns) were analyzed previously published arrays of mammary stem cells (CD24+/CD29+), luminal progenitors 
(CD24+/CD29lo/CD61+) and mature luminal MECs (CD24+/CD29lo/CD61-). 
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MMTV promoter activity, is responsible for the labeling of CD24+/CD29lo cells with 
unique properties in vivo.  
Discussion & Future Directions 
 Using the MMTVrtTA transgenic mouse to induce H2BGFP expression in the 
mammary gland, I have found that H2BGFP induction in the CD24+/CD29lo progenitor-
containing compartment labels a population which contains a multipotent progenitor that is 
specifically activated during pregnancy.  This conclusion that GFP expression distinguishes 
two distinct populations of MECs is corroborated by data from mRNA expression analyses, 
which demonstrate that a large set of transcripts are differentially expressed in 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo cells.  In contrast, I was unable 
to observe any functional differences between the H2BGFP+/CD24+/CD29+ and H2BGFP-
/CD24+/CD29+ populations.   
Figure 4- 11. Cytospin Analysis of MMTVrtTA/H2BGFP Populations. MMTVrtTA/H2BGFP MECswere 
sorted, cytospun and immunostained for various markers.   
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H2BGFP+/CD24+/CD29lo MECs can form small mammary glandular structures in 
vivo, an ability which increases five- to ten-fold when the recipient mice are made pregnant 
post-transplant (Figure 4-2).  H2BGFP-/CD24+/CD29lo MECs are unable to form 
detectable mammary structures in vivo.  H2BGFP+/CD24+/CD29lo-derived outgrowths are 
significantly smaller than outgrowths from CD24+/CD29+ MECs, but have the same 
bilayer structure and cellular composition of normal mammary glands, and are able to 
produce milk; however, H2BGFP+/CD24+/CD29lo-derived mammary structures cannot be 
serially transplanted.  Expression profiling of these MEC populations suggests that they are 
distinct, and that H2BGFP+/CD24+/CD29lo MECs are less differentiated than H2BGFP-
/CD24+/CD29lo MECs.  This provides evidence that the H2BGFP+/CD24+/CD29lo 
compartment contains a population of pregnancy-activated multipotent mammary 
progenitors.   
 These progenitors were identified in a population isolated from female mice during 
early puberty.  The existence of pregnancy-activated progenitors in the mammary gland 
before sexual maturity indicates that these progenitors are produced during pubertal 
development and remain dormant until pregnancy.  For the in vivo growth assays, cleared fat 
pad transplants were performed on three week old mice, and mammary fat pads were 
harvested six weeks later, at the end of puberty, or during late pregnancy.  In 
H2BGFP+/CD24+/CD29lo MEC transplants, few mammary outgrowths had developed in 
virgin mice by the end of puberty, suggesting that the progenitor cells are relatively 
unresponsive to the hormonal signals of puberty and require pregnancy hormones to 
develop an outgrowth detectable by carmine alum staining.  Because pregnancy was induced 
3-4 weeks post-transplant, these pregnancy-activated progenitors apparently survive in virgin 
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mice, but are for the most part unable to develop into detectable mammary epithelial 
structures in the mammary fat pads.   
It is unknown whether H2BGFP-/CD24+/CD29lo cells do not form mammary 
outgrowths in vivo because of a lack of proliferation or a failure to survive.  Further studies 
using these MEC populations in combination with a powerful label, such as luciferase, which 
can be detected by imaging the live animal, could determine whether proliferation, survival 
or both are critical to the activity of mammary progenitors in vivo.   
The evidence that a few mammary outgrowths were found in virgin mice suggests 
that either these H2BGFP+/CD24+/CD29lo MECs can proliferate, albeit minimally, in 
response to pubertal signaling or that H2BGFP+/CD24+/CD29lo MECs contain a mixed 
population of progenitors that respond to puberty and another larger number of progenitors 
that respond to pregnancy.  As the existence of pregnancy-independent multipotent 
mammary progenitors has been reported [35, 36], and the calculated MRU frequencies of 
H2BGFP+/CD24+/CD29lo cells suggest that these MECs represent a mixed population, 
either hypothesis could be correct.  Further purification and in vivo testing of 
H2BGFP+/CD24+/CD29lo MECs is required to determine whether this population contains 
more than one class of multipotent mammary progenitor.   
The results from expression analysis of H2BGFP+/CD24+/CD29lo MECs and 
H2BGFP-/CD24+/CD29lo MECs supports the hypothesis that these populations are 
biologically distinct, and that H2BGFP expression labels a progenitor population within the 
CD24+/CD29lo compartment.  H2BGFP+/CD24+/CD29lo MECs express markedly lower 
levels of transcripts involved in mammary development and differentiation.  These 
transcripts include Sca-1, which is upregulated in differentiated MECs [12], AREG, which is 
required for ductal elongation [117], PRLR and Cav1, which are involved in alveologenesis 
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[118, 119], and FGFR2, which is required for TEB development, mature luminal cell survival 
and alveologenesis [120, 121].  Interestingly, Muc1, which is associated with luminal cells, has 
increased transcript levels in H2BGFP+/CD24+/CD29lo cells, contrasting with the 
multipotent progenitor function of the H2BGFP+/CD24+/CD29lo population.  
Interestingly, when compared with populations of mammary stem cells, luminal progenitors 
and luminal cells as defined by expression of CD24, CD29 and CD61, the 
H2GFP+/CD24+/CD29lo population bore characteristics of both stem cells and luminal 
progenitors.  In particular, it is suggestive that genes  expressed highly in H2BGFP+/ 
CD24+/CD29lo are enriched for luminal progenitor transcripts, while 
H2BGFP+/CD24+/CD29lo MECs share inhibited transcripts with mammary stem cells.  
This implies that the H2BGFP+/CD24+/CD29lo population has a common origin with, or 
may even give rise to CD24+/CD29lo/CD61+  MECs, but are less differentiated than 
luminal progenitors.  These data support my hypothesis that H2BGFP+/CD24+/CD29lo 
MECs contain multipotent progenitors.    
 The CD24+/CD29+ compartment has been reported to contain both mammary stem 
cells and myoepithelial-restricted progenitors [38].  Therefore, a subdivision of the 
CD24+/CD29+ population could represent the differentiation of functionally different MEC 
subtypes.  Expression profiling data from H2BGFP+/CD24+/CD29+ and H2BGFP-
/CD24+/CD29+ MECs independently segregated, suggesting a functional difference 
between these populations.  However, functional proof of this difference has been elusive.  
Similar mammary repopulation rates and outgrowth morphologies of H2BGFP+ and 
H2BGFP- MECs in the CD24+/CD29+ compartment suggest that MMTVrtTA/H2BGFP 
expression does not distinguish between these populations in primary transplants.  Another 
possibility was that H2BGFP expression in the CD24+/CD29+ compartment delineates long 
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term and short term stem cells, which would be expected to have differential repopulation 
abilities in serial transplants.  However, no difference in serial transplant ability was detected 
between these populations.  Given that mammary epithelial cells have demonstrated a limit 
of between four and seven rounds of serial transplantation before they can no longer form a 
detectable gland [122], it is possible that more extensive experimentation could demonstrate 
currently undetected differences between these populations.    
 My unexpected finding from these experiments is that CD24+/CD29+ -derived 
glands maintain the H2BGFP expression of the parental population.  Outgrowths from 
H2BGFP-/CD24+/CD29+ MECs did not express H2BGFP, even when recipients were 
constantly treated with doxycycline.  This result suggests that transcription of either rtTA or 
H2BGFP is epigenetically silenced in the stem/progenitor cells of this population and raises 
questions about the timing and initiation of MMTVrtTA induction of H2BGFP in the 
mammary gland.  Because MECs were transplanted into pubertal females, this data suggests 
that MMTVrtTA/H2BGFP expression is determined (if not necessarily initiated) by three 
weeks of age, and that this fate is inherited by all descendants.  At present, it is unknown 
whether MMTVrtTA induction of H2BGFP is a stochastic event or whether it is due to 
MMTV promoter activity and/or the insertion site of the MMTVrtTA transgene.  However, 
the difference in in vivo repopulating activity and differential gene expression profiles of the 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations suggests that 
H2BGFP delineation of these two populations is not a random event.   
  A secondary goal of the microarray analysis was the identification of potential cell 
surface markers which could replace or even improve upon MMTVrtTA/H2BGFP 
expression for isolation of the H2BGFP+/CD24+/CD29lo population.  As is discussed in the 
Appendix, 24 different candidate cell surface markers were selected from the microarray and 
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from known markers of the mammary stem cell hierarchy and tested for the ability to 
distinguish the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations.  
Although no markers clearly separated these two populations, CD14 was identified as a 
promising potential marker for H2BGFP+/CD24+/CD29lo MECs.  While these experiments 
were being conducted, Visvader and colleagues also identified the 
CD24+/CD29lo/CD14+/c-Kit- population as an alveolar progenitor population based on in 
vitro activity [32].  My findings support the hypothesis that CD14 might act as a marker for 
populations with pregnancy-specific activity.   The CD24+/CD29+ compartment has been 
reported to contain both mammary stem cells and myoepithelial-restricted progenitors [38].  
Therefore, a subdivision of the CD24+/CD29+ population could represent the 
differentiation of functionally different MEC subtypes.  However, the similar mammary 
repopulation rates and outgrowth morphologies of H2BGFP+ and H2BGFP- MECs in the 
CD24+/CD29+ compartment suggest that MMTVrtTA/H2BGFP expression does not 
distinguish between these populations.  Another possibility was that H2BGFP expression in 
the CD24+/CD29+ compartment delineates long term and short term stem cells, which 
would be expected to have differential repopulation abilities in serial transplants.  However, 
no difference in serial transplant ability was detected between these populations.  Given that 
mammary epithelial cells have demonstrated a limit of between four and seven rounds of 
serial transplantation before they can no longer form a detectable gland [122], it is possible 
that more extensive experimentation could demonstrate currently undetected differences 
between these populations.    
 Unexpectedly, these experiments demonstrated that CD24+/CD29+ -derived glands 
maintain the H2BGFP expression of the parental population.  H2BGFP-/CD24+/CD29+ 
MECs were able to give rise to serially transplantable mammary outgrowths that did not 
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express H2BGFP, even when recipients were constantly treated with doxycycline.  This 
result suggests that transcription of either rtTA or H2BGFP is epigenetically silenced in the 
stem/progenitor cells of this population and raises questions about the timing and initiation 
of MMTVrtTA induction of H2BGFP in the mammary gland.  Because MECs were 
transplanted into pubertal females, this data suggests that MMTVrtTA/H2BGFP expression 
is determined (if not necessarily initiated) by three weeks of age, and that this fate is inherited 
by all descendants.  At present, it is unknown whether MMTVrtTA induction of H2BGFP is 
a stochastic event or whether it is due to MMTV promoter activity and/or the insertion site 
of the MMTVrtTA transgene.  However, the different in vivo repopulating activity and 
different gene expression profiles of the H2BGFP+/CD24+/CD29lo and H2BGFP-
/CD24+/CD29lo populations suggests that H2BGFP delineation of these two populations is 
a non-random event. 
Studies have demonstrated that disruption of specific signaling pathways can 
abrogate mammary development during either puberty without affecting alveologenesis, or 
vice versa [123-125].  This has established that mammary proliferation during puberty and 
pregnancy are separate processes, involving different biochemical mechanisms.  The data 
discussed in this chapter of my thesis provides evidence that different mammary epithelial 
cell types are involved in these different modes of mammary development.  While previously 
characterized stem cells are responsible for ductal elongation and formation of the mammary 
tree, a different population of pregnancy-activated progenitors could give rise to the milk-
producing alveoli during pregnancy.  This is supported by the evidence of Smith and 
colleagues, who found a population of parity-induced MECs (PI-MECs) which were able to 
contribute to alveoli during pregnancy, but were unable to form mammary ducts during 
puberty [42, 126].  Furthermore, Van Keymeulen et al., discovered in lineage tracing studies 
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of K8-expressing cells that some of these MECs were able to repeatedly give rise to alveoli, 
but that not all alveoli were derived from K8 lineage cells; this suggests that K8 expression 
identified some, but not all pregnancy-activated progenitors in the mammary gland [38].  My 
data contributes to evidence for a pregnancy-activated multipotent progenitor in the 
mammary gland.   
Further purification and study of the multipotent pregnancy-activated progenitor 
population could further illuminate the dynamics of the mammary gland during pregnancy, 
providing valuable insights about mammary gland biology and breast cancer.   
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Chapter 5 Discussion & Future 
Directions 
 
92 
 
Thesis Summary 
 The original goal of my thesis research was to identify, isolate and characterize 
mouse mammary epithelial cells with stem cell or progenitor activity.  My initial approach 
was to determine whether histone label retention enriches for mammary epithelial stem 
cells/progenitors.  In Chapter 3 of this thesis, I examined transgenic models in which 
H2BGFP was induced in different tissue contexts, using the tetracycline transactivator or the 
reverse tetracycline transactivator under the control of four different promoters.  I found 
that CMVrtTA did not express in the mammary gland.  MMTVtTA and Rosa26rtTA were 
determined to be unsuitable for H2BGFP label retention experiments due to a combination 
of low H2BGFP induction in the mammary gland and potential contamination from non-
mammary tissues expressing H2BGFP.  In the course of these studies, I also observed that 
transplantation of normal MECs into the cleared fat pads of NOD-SCID mice resulted in 
low levels of mammary gland reconstitution, which led to the hypothesis that NOD-SCID 
mammary fat pads lack a critical factor for the development of transplanted MECs.  The 
best model tested expressed the reverse tetracycline transactivator under control of the 
Mouse Mammary Tumor Virus promoter (MMTVrtTA).  This model demonstrated 
mammary-specific induction of H2BGFP, as well as the highest level of H2BGFP 
expression in MECs.   
Histone label retention experiments were performed using the 
MMTVrtTA/H2BGFP transgenic system.  This led to the unexpected observation that 
MMTVrtTA-induced expression of H2BGFP in the mammary gland occurred exclusively in 
MECs within the CD24+/CD29+ and CD24+/CD29lo compartments, which contain stem 
cells and mammary progenitors, respectively.  When MMTVrtTA/H2BGFP label retaining 
cells were tested in transplant assays, they were found to have comparable in vivo 
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reconstitution activity as H2BGFP-expressing MECs prior to label retention.  I concluded 
that histone label retention does not enrich for mammary stem cell/progenitor populations.  
However, MMTVrtTA/H2BGFP expression within the mammary stem cell and progenitor 
compartments could potentially label novel populations within these MEC compartments.  
Interestingly, I found that H2BGFP expression in the CD24+/CD29lo compartment labeled 
a MEC population with the ability to develop into small mammary outgrowths in vivo.  This 
suggested the existence of a subpopulation of multipotent progenitors in the CD24+/CD29lo 
compartment.  At the time of these experiments, CD24+/CD29lo MECs had demonstrated 
no in vivo repopulation ability, and therefore this was a notable finding.   
In Chapter 4 of this thesis, I described my investigations of the functional properties 
of H2BGFP+/CD24+/CD29+, H2BGFP-/CD24+/CD29+, H2BGFP+/CD24+/CD29lo and 
H2BGFP-/CD24+/CD29lo cells.  I found that H2BGFP+ and H2BGFP- populations in the 
CD24+/CD29+ compartment could not be distinguished based on the repopulation activity 
of primary transplants in virgin or pregnant mice, the ability to be serially transplanted or 
behavior in 3D spheroid growth assays.  However, H2BGFP+ cells within the 
CD24+/CD29lo compartment had the ability to develop mammary outgrowths in vivo, while 
H2BGFP-/CD24+/CD29lo MECs were unable to do so.  Althought these outgrowths were 
significantly smaller than the glands derived from CD24+/CD29+ MECs and were unable to 
serially transplant, they contained luminal and myoepithelial/basal cells and were able to 
produce milk.  Further investigations revealed that the repopulating ability of 
H2BGFP+/CD24+/CD29lo MECs is five- to ten-fold higher when recipient mice were made 
pregnant.  Expression analysis of H2BGFP+/CD24+/CD29lo MECs compared to H2BGFP-
/CD24+/CD29lo MECs confirmed that these populations were significantly different, and 
revealed that H2BGFP+/CD24+/CD29lo MECs expressed lower levels of transcripts 
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involved in mammary development and differentiation.  Taken together, these data support 
the hypothesis that the H2BGFP+/CD24+/CD29lo compartment contains a heretofore 
uncharacterized population containing a multipotent, pregnancy-activated mammary 
progenitor.  Further study of the H2BGFP+/CD24+/CD29lo population is required to 
determine which signals trigger pregnancy-activated proliferation, and the function of these 
cells in repeated pregnancies. 
In the Appendix of this thesis, I described further experiments to evaluate candidate 
cell surface markers for isolation of the pregnancy-activated multipotent progenitors 
contained within the H2BGFP+/CD24+/CD29lo population.  These markers were selected 
from genes that are differentially regulated in H2BGFP+/CD24+/CD29lo and H2BGFP-
/CD24+/CD29lo cells as assessed by my microarray experiments, and from previously 
identified markers of the mammary stem cell hierarchy.  Unfortunately, no single marker or 
combination of tested markers was able to separate the H2BGFP+/CD24+/CD29lo and 
H2BGFP-/CD24+/CD29lo.  However, six markers (CD14, CD49b, EpCAM, FGF2, Jag1 
and Sca-1) demonstrated some degree of separation between the H2BGFP+/CD24+/CD29lo 
and H2BGFP-/CD24+/CD29lo populations, suggesting that these markers could be used 
alone or in combination to separate the pregnancy-activated multipotent progenitor 
population from the bulk of the CD24+/CD29lo MECs.  Further flow cytometry analysis 
demonstrated that CD14 alone was the most promising candidate marker.  Unfortunately, 
transplants of CD24+/CD29lo/CD14+ and CD24+/CD29lo/CD14- MECs in virgin and 
pregnant mice resulted in a mammary repopulation rate far greater than was predicted based 
on analysis of CD14 expression in the CD24+/CD29lo compartment and my previous 
transplant experiments.  This result might have been due to an unusually high concentration 
of growth factors or other biochemical components within the Matrigel used for these 
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injections.  More extensive experiments are required to determine which critical factors in 
Matrigel encourage mammary development, and whether or not they have a physiological 
role.  Simultaneous with these experiments, another group reported that 
CD24+/CD29lo/CD14+/c-Kit- MECs can rise to lactogenic colonies in vitro [32], providing 
evidence for CD14 as a strong candidate marker for isolation of pregnancy-activated 
multipotent progenitors in the mammary gland.   
My findings contribute to the increasing body of work on the mammary epithelial 
stem cell hierarchy, and provide evidence that mammary development during puberty and 
pregnancy are separate processes, involving not only different signaling pathways, but 
different target cells.   
Histone Label Retention in the Mammary Gland 
 Evidence for label retaining cells with stem/progenitor function in the mammary 
epithelium was first provided by the work of Smith and colleagues through experiments in 
which DNA-based labels and estrogen-enhanced pubertal proliferation were utilized to 
identify mammary LRCs [86].  These LRCs were found to be actively cycling, which was 
interpreted as evidence for immortal strand retention, and to express ER and PR [89].  These 
LRCs also were found to contribute to alveologenesis during successive pregnancies [89].  
Notably, subsequent work demonstrated that expression of steroid hormone receptors is 
absent in mammary stem cells (CD24+/CD29+ and CD24+/CD49f+), whereas ~40% of the 
more differentiated CD24+/CD29lo compartment expresses ER and/or PR [40].  These 
results suggest that either DNA label retention identifies a new class of mammary stem cells 
with steroid hormone receptor expression and activity in pregnancy, or that these LRCs are 
progenitor cells, with persistent proliferation capacity during pregnancy.   
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 Label retention assays have been used previously to identify putative stem cells and 
stem cell niches [72, 76, 77]; however, label retention can be technically difficult and 
functionally limited.  Adult stem cells are believed to retain label due to either relative mitotic 
quiescence or asymmetric division of labeled molecules. In either case, label dilution can still 
occur, resulting in a difficult-to-detect signal, particularly if the tissue in question does not 
have a niche containing a concentration of stem cells, such as the epidermal bulge.  
Additionally, DNA label retention using molecules such as BrdU or tritiated thymidine does 
not permit the isolation of live LRCs, limiting the ability to test the functional properties of 
LRCs.  New developments in DNA labeling, such as the use of nucleotide analogs with 
native fluorescence, might eventually eliminate this difficulty [127].   
Currently, the best tool for isolation of LRCs is the tetracycline-inducible H2BGFP 
transgenic mouse.  However, as demonstrated in Chapter 2, H2BGFP pulse-chase 
experiments are limited by the availability of transgenic models able to direct expression of 
H2BGFP in the desired tissue.  Rosa26rtTA and MMTVtTA were able to induce H2BGFP 
expression in the mammary gland, but not exclusively.  Unfortunately, the mammary gland is 
a highly heterogeneous tissue and label retention experiments necessarily result in the 
isolation of a small percentage of cells; therefore, H2BGFP+ non-epithelial cells in the 
mammary gland are a potential source of contamination.  This problem could be 
circumvented by transplanting H2BGFP-induced MECs into the cleared fat pad of a non-
H2BGFP mouse, and monitoring H2BGFP label dilution during pubertal expansion; this 
would, however, greatly increase the expense and difficulty of generating enough LRCs for 
stem cell/progenitor assays.   
 I performed H2BGFP label retention experiments using the Rosa26rtTA and 
MMTVrtTA transgenic systems.  Transplants of the Rosa26rtTA/H2BGFP LRCs produced 
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disappointing results, most likely due to a defect in the NOD-SCID mammary fat pad. 
However, these transgenic mice might still be used to isolate mammary LRCs, after a 
backcross of both strains into the same genetic background and with due consideration for 
potential contamination from non-mammary lineages.  LRCs isolated from the 
MMTVrtTA/H2BGFP system demonstrated no enrichment in mammary stem 
cells/progenitors after pubertal dilution of H2BGFP signal.  However, given the evidence 
that pubertal, estrous and pregnancy-associated expansion of the mammary gland are 
separate processes [35, 123, 124, 128, 129], it is possible that label retention assays conducted 
using repeated estrus cycles or pregnancies could result in the isolation of LRCs with novel 
stem/progenitor functions.   
 Alternatively, future H2BGFP label retention experiments could utilize tetracycline-
inducible strains distinct from the ones that I examined in this thesis research.  For example, 
a model where the CD24+/CD29+ compartment was completely labeled at the beginning of 
a label retention experiment could allow the isolation of functionally significant LRCs in this 
compartment.  However, each of these transgenic models would require thorough 
characterization and testing to ensure that the desired pulse-chase kinetics are achieved.  For 
example, one study has reported the use of CK14rtTA to induce H2BGFP in the mammary 
gland, resulting in induction only in the myoepithelial/basal layer [130]; use of this strain 
would result in myoepithelial lineage-specific LRCs.  The reverse tetracycline transactivator 
driven by the cytokeratin 5 promoter (CK5rtTA) was used for H2BGFP label retention in 
the epidermis, and could also be used in the mammary gland, as early mammary epithelial 
lineages are known to express CK5 [85]; however, lineage tracing studies have suggested that 
K5 is also active exclusively in the myoepithelial layer of the adult mammary gland, which 
could limit use of K5rtTA in H2BGFP LRC studies [38].  Tetracycline transactivators under 
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the control of pregnancy/lactation-dependent promoters, such as BLG, would require 
pregnancy and lactation for induction, and possibly for label dilution as well; a label retention 
study using the WAPrtTA/H2BGFP system has been reported, with inconclusive results on 
the survival of LRCs after involution  [87, 131].   
 The lack of a reliably mammary-specific promoter with pre-pregnancy activity has 
been a long-standing technical difficulty in mammary gland research.  However, this 
drawback could result in adaptations of the label retention assay that could lead to new 
discoveries.  For example, label dilution through mammary proliferation during estrus or 
pregnancy could be explored productively.  Alternatively, tetracycline transactivator strains 
under the control of lineage-specific promoters such as CK14 could identify myoepithelial or 
luminal LRCs.  It remains possible that H2BGFP label retention could provide valuable new 
insights into the mammary stem cell hierarchy, but thorough consideration of the technical 
and scientific limitations is required for productive experimentation and analysis of label 
retention in the mammary gland.   
Evidence for a pregnancy-activated multipotent progenitor in the 
H2BGFP+/CD24+/CD29lo population 
Investigations of mammary development have found evidence for a mammary stem 
cell hierarchy, consisting of stem cells capable of reconstituting the original mammary gland 
[12, 13], multipotent progenitors capable of giving rise to more than one mammary subtype 
[35, 38], unipotent progenitors committed to producing single-lineage MECs [32, 38] and 
differentiated cells with limited to no proliferation capacity [38, 116].  The roles that these 
MEC populations play during different stages of mammary development are still being 
characterized.  Mammary stem cells are involved in the establishment of the mammary 
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architecture during puberty, and studies demonstrating the expansion of the CD24+/CD49f+ 
stem cell compartment during estrus and pregnancy suggest that mammary stem cells also 
proliferate during estrus and pregnancy expansion [2, 132].  However, a lineage-tracing study 
found that non-stem populations within the CD24+/CD29+ compartment, which 
corresponds with the  CD24+/CD49f+ population, include myoepithelial cells that can 
expand during pregnancy [38].  Additionally, mammary glands that are missing luminal 
progenitor populations, as a consequence of the deletion of Stat5A/5B or expression of 
mutant cyclin D1, can form normal mammary glands but were unable to undergo 
alveologenesis [35, 123, 124].   If pregnancy proliferation was only dependent on stem cells, 
the loss of a pre-pregnancy progenitor population should not affect alveologenesis.  These 
data support the rival hypothesis that while stem cells are involved in mammary pubertal 
proliferation, progenitors give rise to alveoli during pregnancy.   
Studies that have examined the disruption of signaling pathways in the mammary 
gland have established that mammary proliferation during puberty and pregnancy are 
separate functions.  Pubertal mammary development is dominated by estrogen signaling, 
whereas estrus and pregnancy proliferation in the mammary gland are progesterone-
dependent.  Loss of Stat5A/5B or CyclinD1 in the mammary gland results in the 
development of morphologically normal glands that are unable to develop alveoli during 
pregnancy; both Stat5A/5B- and CyclinD1- deficient mammary glands lack 
CD24+/CD29lo/CD61+ luminal progenitors [35, 123, 124].  Interestingly, mice missing 
Stat5A in the mammary gland or expressing mutant CyclinD1 demonstrate increased latency 
in the development of mammary tumors, suggesting that these missing progenitors could be 
important for tumorigenesis [35, 133].  Mice expressing a dominant negative form of ErbB2 
in the mammary gland develop normally, but form incomplete alveoli during pregnancy and 
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cannot lactate [128].  Conversely, mammary glands that overexpress Tgfβ and or lack 
amphiregulin are severely defective in ductal development, but can form alveoli in response 
to pregnancy [117, 129].  In some of these studies, it was not established conclusively that 
the observed defect was due to a missing mammary cell population; however, further 
examination of these mammary development models might reveal which mammary 
stem/progenitor cells are directly responsible for pubertal vs. pregnancy proliferation.   
The goal of my studies was to identify and characterize novel mammary stem 
cell/progenitor populations and investigate their role in various stages of mammary 
development.  Although puberty-mediated label retention in the MMTVrtTA/H2BGFP 
transgenic system did not enrich for mammary stem cells or progenitors in the LRCs, I made 
the serendipitous discovery that the H2BGFP+/CD24+/CD29lo population could give rise to 
diminutive mammary structures in vivo.  These outgrowths reproduced the original mammary 
cell composition and structure, and could produce milk when recipient mice were made 
pregnant (Figure 4-7).  At the time these experiments were conducted, this finding was 
unexpected because CD24+/CD29lo MECs were initially reported to contain luminal 
progenitors and to have no in vivo repopulation activity [12].  Because 
H2BGFP+/CD24+/CD29lo MECs were found to have a mammary repopulating unit 
frequency of 1/710 in the initial experiments (Figure 3-21), and these MECs comprised only 
~15% of the CD24+/CD29lo compartment (Figure 3-14), these cells would have gone 
undetected in the limiting dilution transplants described by Shackleton et al. [12].   
 When the H2BGFP+/CD24+/CD29lo transplant data were analyzed with respect to 
the pregnancy status of the recipient mice, I found that pregnancy increased the mammary 
repopulation ability of these MECs five- to ten-fold (Figure 4-2, 4-6).  These data, in 
combination with the fact that these structures could not serially transplant (Figure 4-1), 
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suggested that MMTVrtTA-induced H2BGFP expression in the CD24+/CD29lo 
compartment labeled a population containing pregnancy-activated multipotent progenitors.  
Because this population was isolated from female mice during early puberty, and because 
immunofluorescence data suggests that H2BGFP+/CD24+/CD29lo MECs are located at 
intervals in the luminal layer of the mammary gland, I surmise that these pregnancy-activated 
progenitors are established in the mammary gland along with the rest of the ductal 
architecture, but remain dormant until stimulated by signals generated during pregnancy.   
 Because mammary outgrowths were detected in both virgin and pregnant mammary 
glands, although at drastically different rates, it also is possible that the 
H2BGFP+/CD24+/CD29lo population contains two types of progenitors, one that helps 
mammary gland growth during puberty, and a progenitor that is present in higher numbers 
and is active only during pregnancy.  The studies that reported in vivo mammary proliferation 
in CD24+/CD29lo and CD24+/CD49flo cells were performed in virgin mice, suggesting the 
existence of puberty-activated multipotent mammary progenitors [35, 36].  Because 
pregnancy would occur after the bulk of pubertal mammary development had taken place, 
the data from my pregnancy experiments would include outgrowths from both puberty- and 
pregnancy-specific progenitors.  One method that could be employed to address whether 
more than one progenitor is present in the H2BGFP+/CD24+/CD29lo population would be 
to express a more readily detectable biomarker, such as luciferase, in the 
H2BGFP+/CD24+/CD29lo cells prior to transplant.  Regular body scans of 
H2BGFP+/CD24+/CD29lo transplant recipient mice could detect the dynamics of 
H2BGFP+/CD24+/CD29lo-derived outgrowths, and determine whether these cells 
proliferate in response to puberty and pregnancy, or only pregnancy.  Alternatively, co-
transplantation of H2BGFP+/CD24+/CD29lo and unlabeled CD24+/CD29+ MECs, 
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followed by tracing the contribution of H2BGFP+/CD24+/CD29lo-derived cells to the 
mammary gland during puberty and pregnancy could determine whether or not the 
H2BGFP+/CD24+/CD29lo population contains puberty progenitors.  At present, I can 
conclude only that H2BGFP+/CD24+/CD29lo contains a population of multipotent 
progenitors with preferential proliferation during pregnancy.   
 Evidence for the existence of pregnancy-specific progenitors has been reported by 
the Smith and Wagner labs, who utilized the WAP-cre/LacZ transgenic system to carry out 
lineage tracing of pregnancy-activated cells.  This resulted in the labeling of parity-induced 
MECs (PI-MECs) which were found to give rise to alveoli over multiple pregnancies [42].  
As was the case with the H2BGFP+/CD24+/CD29lo pregnancy-activated progenitors, PI-
MECs were found to exist in the mammary gland prior to pregnancy, suggesting that their 
cell fate was established during puberty [43].  Although PI-MECs were initially reported to 
have no mammary repopulating ability in vivo, a later study found that they could occasionally 
give rise to fully functional mammary glands and that they contained a small population of 
CD24+/CD49f+ stem cells [44].  The H2BGFP+/CD24+/CD29lo population might contain 
more than one kind of mammary progenitor, but all of my experiments have indicated that 
these MECs have no self-renewal capacity, as is indicated by their lack of serial transplant 
activity.  Because transplant recipient mice were made pregnant only once, I can draw no 
conclusion about whether the H2BGFP+/CD24+/CD29lo progenitor can give rise to 
repeated mammary outgrowths in vivo.   Experiments that track the in vivo kinetics of the 
transplanted H2BGFP+/CD24+/CD29lo population across multiple pregnancies, similar to 
the one described above to determine whether this population contains puberty-specific 
progenitors, could determine whether these pregnancy-activated progenitors can proliferate 
during multiple pregnancies.   
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 It is notable that expression of CD61, which has been found to distinguish between 
luminal progenitors and mature luminal cells within the CD24+/CD29lo compartment [116], 
did not differ between the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo 
populations (Figure A-3i).  This result, in combination with comparison of gene expression 
profiles of CD24+/CD29lo MECs distinguished by CD61 expression (Figure 4-10) provides 
convincing support for the idea that H2BGFP expression in the CD24+/CD29lo identifies a 
different and probably novel mammary progenitor.  It is possible that 
MMTVrtTA/H2BGFP expression in the CD24+/CD29lo compartment labels pregnancy 
progenitors, whereas CD61 expression identifies CD24+/CD29lo progenitors with activity 
during puberty.  Interestingly, Jeselsohn et al. found that CD24+/CD49flo MECs, which were 
also initially found to have no in vivo repopulating ability, could give rise to mammary 
outgrowths in both pregnant and virgin hosts, also suggesting the existence of mammary 
progenitors which do not require the stimulus of pregnancy for in vivo repopulation activity; 
it is also notable that development of these outgrowths required co-injection of Matrigel.  
The pregnancy activation experiments described in this thesis and by Jeselsohn et al. could 
be applied to other MEC populations to discover any pregnancy-specific activities of other 
mammary progenitor populations [35].   
In contrast to the differential cell activity found in the CD24+/CD29lo populations, 
my studies found no functional difference in the H2BGFP+/CD24+/CD29+ and H2BGFP-
/CD24+/CD29+ populations.  H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+ 
MECs had similar mammary repopulation rates in pregnancy and in virgin mice (Figure 4-2) 
and the same serial transplantation ability (Figure 4-1).  The main difference between these 
populations was that their descendants inherited the H2BGFP status of the original stem 
cell.  This raises the question of how H2BGFP was induced in the CD24+/CD29+ 
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compartment and whether this affects H2BGFP expression in the downstream 
CD24+/CD29lo compartment.  All of the functional evidence points to distinct differences 
between the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations, 
making it more likely that H2BGFP expression is induced rather than epigenetically inherited 
in the CD24+/CD29lo population.  Additionally, expression analysis was able to separate the 
H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/CD29+ populations, suggesting that 
these populations might have different functions which have not been detected by the assays 
already conducted.  Although further studies could discover a functional difference between 
the CD24+/CD29+ populations, I conclude, based on the current evidence, that the most 
likely possibility is that MMTVrtTA/H2BGFP expression in this compartment is stochastic 
and without significance to the mammary epithelial stem cell hierarchy.   
 Expression analysis also provides evidence that the H2BGFP+/CD24+/CD29lo 
population contains a population of progenitors distinct from the bulk H2BGFP-
/CD24+/CD29lo population.  A significant number of genes involved in mammary 
development and differentiation are expressed at lower levels in the 
H2BGFP+/CD24+/CD29lo population, which is consistent with biological differences 
between the two CD24+/CD29lo populations.  For example, Esr1 and AREG are required 
for ductal elongation, a process limited to pubertal proliferation [117, 129].  An analysis of 
genes which differ between H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo 
MECs in a previously reported microarray of mammary stem, luminal progenitor and mature 
luminal populations found that H2BGFP+/CD24+/CD29lo expression had striking 
commonalities with both stem cells and luminal progenitors[116].  
H2BGFP+/CD24+/CD29lo MECs express genes highly in common with 
CD24+/CD29lo/CD61+ luminal progenitors, but repress other transcripts in common with 
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the mammary stem cell compartment, suggesting the possibility that they either share a 
common origin with or give rise to luminal progenitors.  This analysis supports the role of 
H2BGFP+/CD24+/CD29lo MECs as a multipotent mammary progenitor.  In all of the 
mammary transplant studies described in this thesis, MEC populations were co-injected with 
basement membrane matrix, growth factor reduced Matrigel™.  This is notable because 
although CD24+/CD29lo MECs were originally observed to have in vivo activity, Valliant et 
al. later observed that CD24+/CD29lo MECs could form small mammary outgrowths if co-
injected with Matrigel [36].  Another study found that CD24+/CD49flo MECs, which also 
were also originally reported to have no in vivo activity, formed lobular-alveolar structures in 
both virgin and pregnant mice in the presence of Matrigel [35].  These data contribute to a 
growing body of evidence for an unknown component or growth factor in Matrigel that 
increases transplant uptake, by assisting either cell survival or proliferation [134].  
Additionally, lineage tracing demonstrated that myoepithelial-limited progenitors could give 
rise to mammary gland structures in vivo, but only if co-injected with a critical ratio of luminal 
cells, suggesting that paracrine signals can alter progenitor cell activity in vivo [38].  It is 
notable that in previous studies, neither Matrigel nor the addition of other mammary cells 
was able to affect the mammary growth protential of the stem cell compartments identified 
by expression of CD24+/CD29+ or CD24+/CD49f+ [12, 36].  Determining which additional 
components required for in vivo progenitor activity are fulfilled by the addition of Matrigel, 
and whether these components are involved in normal mammary development, would 
contribute to our understanding of mammary development.   
 Altogether, this thesis provides evidence that H2BGFP+/CD24+/CD29lo MECs 
contain a population of pregnancy-activated multipotent mammary progenitors.  Future 
directions for this project could include experiments to understand the basis for the 
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pregnancy-specific activity of H2BGFP+/CD24+/CD29lo MECs; mice transplanted with 
H2BGFP+/CD24+/CD29lo MECs could be treated with pregnancy hormones, such as 
progesterone and prolactin, to determine which signals trigger H2BGFP+/CD24+/CD29lo 
outgrowths.  Alternatively, H2BGFP+/CD24+/CD29lo MECs could be co-transplanted with 
defined extracellular matrix components and/or growth factors to determine which are most 
crucial to mammary progenitor activity in vivo.  H2BGFP+/CD24+/CD29lo MECs could also 
be co-transplanted with unlabeled populations of different MEC subtypes, such as 
CD24+/CD29+ cells or CD24+/CD29lo/CD61± populations to determine if paracrine 
signaling from these MECs can affect the in vivo repopulating ability of 
H2BGFP+/CD24+/CD29lo MECs.  Additionally, co- transplantation of 
H2BGFP+/CD24+/CD29lo MECs with unlabeled CD24+/CD29+ cells could determine the 
contribution of H2BGFP+/CD24+/CD29lo MECs to the mammary gland during puberty 
and pregnancy.  Additionally, in vivo development of H2BGFP+/CD24+/CD29lo MECs 
could be monitored to elucidate the dynamics of H2BGFP+/CD24+/CD29lo activity during 
different stages mammary development.   
Although the ability to repopulate the cleared mammary fat pad remains the best in 
vivo assay for mammary stem cells/progenitors, the development of mammary glands from 
transplanted MECs is a non-physiological phenomenon.  Transplanted MECs do not 
undergo any of the stages of mammary development prior to three weeks of age.  Therefore, 
mammary fat pad transplants might detect progenitors responsible for mammary 
proliferation during puberty, rather than stem cells.  Serial transplant studies have found that 
normal mammary glands can be transplanted 4-7 times, and that later transplants give rise to 
outgrowths of diminishing size [122].  As stem cells theoretically can propagate indefinitely, 
this gradual decrease in proliferative ability suggests that transplant assays either select for 
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progenitor-derived outgrowths, or that the transplantation process itself causes stem cells to 
terminally differentiate.   
The lineage tracing study conducted by Van Keymeulen et al. found that all 
mammary lineages are descended from embryonic MECs expressing CK14.  However, they 
were unable to identify a post-natal MEC population which gave rise to more than a single 
mammary lineage, without transplantation.  Under the physiological conditions of mammary 
development, this study found no evidence of a post-natal mammary stem cell, and 
demonstrated that a bipotent cell fate can be artificially induced in a myoepithelial progenitor 
when transplanted with luminal cells [38].  It is possible that H2BGFP+/CD24+/CD29lo 
repopulation is the result of contamination and co-transplantation, and that furthermore, the 
pregnancy activation observed is the result of increased paracrine signaling between luminal 
cells and myoepithelial progenitors.  Since the myoepithelial progenitors described by Van 
Keymeulen et al. are CD24+/CD29+, this is unlikely, but still possible.   
The best strategy to eliminate the posibility of artificial differentiation through 
transplantation in the H2BGFP+/CD24+/CD29lo MECs would be to conduct a lineage 
tracing study.  However, the only tool for investigating the H2BGFP+/CD24+/CD29lo 
population at present is the MMTVrtTA/H2BGFP model.  Unfortunately, use of the 
MMTVrtTA transgenic system in a lineage tracing study is unlikely to be informative, since 
MMTVrtTA is active in CD24+/CD29+ populations as well as CD24+/CD29lo populations.  
This consideration also precludes use of the MMTVrtTA model to selectively kill, transform 
or otherwise manipulate the H2BGFP+/CD24+/CD29lo population.  Unless other methods 
are found to identify the H2BGFP+/CD24+/CD29lo population, study of these MECs is 
limited to use of the MMTVrtTA/H2BGFP system and transplantation assays.   
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Candidate Cell Surface Markers for the H2BGFP+/CD24+/CD29lo 
population 
 Although mammary epithelial subpopulations have been identified by various 
indirect means, such as histology [26] and mammary outgrowth analysis [37], isolation of 
MEC populations through the use of cell surface markers and FACS remains the most 
reliable tool for characterization of MEC subtypes.  MEC subpopulations that have been 
identified by cell surface markers include stem cells (CD24+/CD29+, CD24+/CD49f) [12, 
13], luminal progenitors (CD24+/CD29lo/CD61+) [116], myoepithelial progenitors (non-
stem CD24+/CD29+, CD24loCD49f+) [13, 38], mature luminal cells (CD24+/CD29lo/CD61-) 
[116] and alveolar progenitors (CD24+/CD29lo/CD14+/c-Kit-) [33].   
 In the Appendix of this thesis, I describe the testing and evaluation of various 
candidate cell surface markers for the H2BGFP+/CD24+/CD29lo population.  Candidates 
were selected from cell surface markers identified in microarray experiments and from 
markers already known to identify populations of interest in the mammary gland.  Of the 
twenty-four candidate markers tested, six displayed differences in expression between 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo cells, and only one, CD14, was 
found to express in the majority of the H2BGFP+/CD24+/CD29lo population.  
Unfortunately, in vivo testing of this marker was inconclusive because of an unusually high 
repopulation rate of transplanted MECs, which might be the result of an anomalous lot of 
Matrigel.  Repetition of these experiments with a different lot of Matrigel would probably 
demonstrate that CD14 is able to isolate pregnancy-specific mammary progenitors.   
 The identification of CD14 as an upregulated transcript and potential cell surface 
marker for the H2BGFP+/CD24+/CD29lo population has interesting implications.  Asselin-
Labat et al have identified CD24+/CD29lo/CD14+/c-Kit- MECs as alveolar progenitors [32, 
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33].  However, this classification is based on in vitro testing and immunostaining of mammary 
glands, and has not yet been verified in vivo.  One possible future experiment could involve 
lineage tracing, using the CD14 promoter to identify these cells and their descendants in situ.  
Further studies may identify other markers which, in combination with CD14, can isolate the 
pregnancy-activated multipotent progenitors within the H2BGFP+/CD24+/CD29lo 
population.   
Final Note 
 Although much progress has been made, the mammary epithelial stem cell hierarchy 
remains incompletely understood.  In this thesis, I have presented evidence for a pregnancy-
activated multipotent mammary progenitor.  This supports the hypothesis that different cell 
types as well as different signaling pathways are activated during the fundamentally distinct 
processes of pubertal mammary proliferation and pregnancy-mediated alveologenesis.  
Future directions for this project include identifying other cell surface markers for isolation 
of this population, elucidating unknown factors involved in progenitor activity such as 
Matrigel, and studying the dynamics of pregnancy-activated progenitors in vivo. 
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Appendix A Testing Candidate Cell 
Surface Markers for Independent 
Isolation of the 
H2BGFP+/CD24+/CD29lo Population 
by FACS 
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Introduction 
 In the course of histone label retention experiments, I found that MMTVrtTA-
induced expression H2BGFP in the mammary gland labeled a sub-population of the 
CD24+/CD29lo compartment that contained a novel multipotent progenitor with pregnancy-
specific activity.  Further study of this progenitor could provide valuable new insights into 
the mechanisms of proliferation in the mammary gland at different stages of development.  
However, studies of the H2BGFP+/CD24+/CD29lo population are currently limited by the 
need to use the MMTVrtTA/H2BGFP transgenic mouse system to isolate these MECs.   
 To further characterize these progenitors, I carried out transcription profiling of the 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations, as was described in 
Chapter 3.  A secondary goal of these microarrays was to identify cell surface proteins that 
might be candidate markers for separating these populations by FACS.  Ideally, such a 
marker would be strongly expressed in the cell subtype of interest, allowing for positive 
selection, and have commercially available antibodies already shown to be effective for flow 
cytometry.  As the H2BGFP+/CD24+/CD29lo population is mixed and additional purity 
could be obtained from a more selective marker, a marker that labeled only a fraction of 
H2BGFP+/CD24+/CD29lo cells would be considered a strong candidate marker.  
Alternatively, two or more markers could be combined to isolate the population.  Based on 
the microarray data, I tested candidate cell surface markers for the 
H2BGFP+/CD24+/CD29lo population.  This appendix reports the results of these 
experiments and additional considerations for future research on the mammary epithelial 
stem cell hierarchy.   
Results 
112 
 
Candidate cell surface markers for independent isolation of 
H2BGFP+/CD24+/CD29lo MECs 
 Candidate cell surface markers for separation of the H2BGFP+/CD24+/CD29lo 
population from the H2BGFP-/CD24+/CD29lo MECs were selected based on various 
factors.  These selection criteria included differential expression detected by microarray, 
availability of commercial antibodies, previous identification as a marker in the mammary 
stem cell hierarchy and identification as a marker in other adult stem cells/progenitors or 
developmental pathways.   
 In order to identify potential cell surface markers, the 256 microarray probes 
demonstrating statistically significant differences between H2BGFP+/CD24+/CD29lo and 
H2BGFP-/CD24+/CD29lo populations were surveyed for cell surface proteins as identified 
by the Gene Ontology database (Figure A-1).  Candidate markers selected from this group 
included mucin 1 (Muc1, expressed in luminal cells), Alcam, CD86, Ly6a/Sca-1 (expressed in 
differentiated MECs [12]), FGFR2 and Il1R1.  Other candidate markers not on the Gene 
Ontology list were identified from the microarray (Figure A-2), including CD138/syndecan, 
CD14, CD55, CD164, CXCL16, interleukin 33 (Il33), jagged 1 (Jag1), osteoactivin,  AREG 
and PRLR.  Markers selected on the basis of previous identification in the mammary stem 
cell hierarchy or other adult stem cell populations include CD44 [135], CD49b [31], CD61 
[136], EpCam [137], E-cadherin and c-Kit.  A different CD24 antibody from the one used in 
previous assays was selected based on evidence that mammary progenitors and stem cells 
could be distinguished by their level of CD24 expression using this clone(i.e. CD24mid vs. 
CD24hi) [34, 35].   
 To test the selected antibodies, MECs were isolated from four week-old 
MMTVrtTA/H2BGFP mice and stained with the antibodies for candidate cell surface 
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markers, in addition to the markers used in the original analysis.  The 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations were gated and 
analyzed for staining of the experimental antibody; histograms of isotype controls or MECs 
stained only with secondary antibodies were used as control curves for comparison.  A total 
of twenty-four candidate cell surface markers were assayed in at least three different 
experiments (Figure A-3).   
 Of the twenty-four markers tested, none demonstrated a complete separation of 
H2BGFP+/CD24+/CD29lo cells from the H2BGFP-/CD24+/CD29lo population, nor were 
any identified as marking only part of the H2BGFP+/CD24+/CD29lo population.  Thirteen 
antigens (AlCAM, AREG, CD44, CD55, CD86, CD138, CD164, CXCL16, E-cadherin, Il33, 
Muc1, osteoactivin, PRLR) showed equivalent levels of expression between 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo cells.  Five candidate markers 
(CD24, CD49f, CD61, c-Kit, IL1R1) demonstrated minimal differences in expression level 
between the two populations.  Because all of these antibodies, except for the IL1R1 
Figure A-1. Expression of Cell Surface Markers in CD24+/CD29lo Populations. Of the 257 probes found to 
demonstrate statistically significant differences between H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo 
populations, these probes were identified as cell surface proteins by the Gene Ontology database. 
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antibody, have been used repeatedly in flow cytometric studies, it can be concluded that 
these data accurately represent the protein expression level of these candidate markers on 
the cell surface of the tested MEC populations.   
Six markers (CD14, CD49b, EpCAM, FGFR2, Jag1, Sca-1) were expressed 
differentially in the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations.  
Although none of these antibodies clearly distinguished the H2BGFP+ from the H2BGFP- 
populations, the histograms for these antibodies suggested possibly different sub-
populations with distinct properties.  For example, most H2BGFP+/CD24+/CD29lo MECs 
were CD14+, whereas the H2BGFP-/CD24+/CD29lo compartment contained a mixed 
population of CD14+ and mostly CD14- MECs.  H2BGFP+/CD24+/CD29lo MECs were 
found to be Sca-1-, but H2BGFP-/CD24+/CD29lo MECs contained both Sca-1+ and Sca-1- 
cells.  H2BGFP+/CD24+/CD29lo MECs expressed higher levels of CD49b than H2BGFP-
/CD24+/CD29lo MECs, but there was no obvious separation of CD49b subpopulations  
Figure A-2. Expression of Candidate Cell Surface Markers in CD24+/CD29lo Populations. Transcripts identified as 
candidate stem cell markers for separation of H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations in 
the MMTVrtTA/H2BGFP microarray.    
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Figure A-3. Flow Cytometric Analysis of Candidate Cell Surface Markers. MMTVrtTA/H2BGFP MECs were stained 
for antibodies for candidate cell surface markers.  Staining was compared between H2BGFP+/CD24+/CD29lo (green) 
MECs, H2BGFP-/CD24+/CD29lo (red) MECs and control (gray). 
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within these compartments.  The EpCAM, FGFR2 and Jag1 histograms also suggested a 
mixed H2BGFP-/CD24+/CD29lo population, but these differences were not sufficiently 
large for FACS isolation to be attempted.  Based on this data, I concluded that CD14 and 
CD49b were the best candidates for cell surface markers able to enrich for 
H2BGFP+/CD24+/CD29lo MECs.   
To determine whether these were suitable markers for alternative isolation of 
H2BGFP+/CD24+/CD29lo MECs, CD14 and CD49b were tested, both individually and in 
combination, for their ability to enrich for H2BGFP+ cells in the CD24+/CD29lo CD14 as a 
marker of pregnancy-activated multipotent progenitors in the mammary epithelium.  Based 
on the above experiments, I determined that CD14 was the most promising candidate cell 
surface marker for isolation of the multipotent pregnancy-activated progenitors within the 
H2BGFP+/CD24+/CD29lo population.  In the microarray, CD14 transcript levels were 
found to be slightly elevated in H2BGFP+/CD24+/CD29lo MECs compared with 
H2BGFP-/CD24+/CD29lo MECs.  This is consistent with the flow cytometry data, which 
found that H2BGFP+/CD24+/CD29lo cells were almost entirely CD14+, whereas H2BGFP-
/CD24+/CD29lo cells contained a mixed population of CD14+ and CD14- cells (Figure A-
3c).  populations (Figure A-4).  In these experiments, 21±4.7% of CD24+/CD29lo MECs 
were GFP+.  The GFP+ population was 33±4.4% of CD24+/CD29lo/CD14+ MECs and 
35±2.5% of CD24+/CD29lo/CD49b+ cells (Figure A-4f, i).  (Averages and standard 
deviations were derived from n= 3)  However, CD24+/CD29lo/CD14+/CD49b+ MECs 
were 35±6.3% GFP+, demonstrating no additional enrichment when CD14 and CD49b 
were used in combination.  CD14 was determined to be the better marker for subdivision of 
the CD24+/CD29lo compartment because CD14 divides  
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Figure A-4. CD14 and CD49b as markers for H2BGFP+/CD24+/CD29lo MECs. CD14 and CD49b were tested 
separately and in combination as potential markers for isolation of H2BGFP+/CD24+/CD29lo MECs.  Analysis of a) 
GFP expression in total MECs b) CD14 expression in H2BGFP+ vs. H2BGFP- populations c) CD49b expression in 
H2BGFP+ vs. H2BGFP- populations d) CD14 expression in CD24+/CD29lo population e) correlation of GFP and CD14 
in CD24+/CD29lo population f) GFP expression in CD24+/CD29lo/CD14+ g) CD49b expression in CD24+/CD29lo 
population h) correlation of GFP and CD49b in CD24+/CD29lo population i) GFP expression in 
CD24+/CD29lo/CD49b+ j) CD14 and CD49b expression in CD24+/CD29lo population k) GFP expression in 
CD24+/CD29lo/CD14+/CD49b+ 
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the CD24+/CD29lo population into distinct CD14+ and CD14- populations, whereas CD49b 
expression was less distinct (Figure A-4b, c).  (Averages and standard deviations were 
derived from an n = 4) 
The CD24+/CD29lo/CD14+ population contained 78±6.2% of the 
H2BGFP+/CD24+/CD29lo population; however, 63±3.5% of the CD24+/CD29lo/CD14+ 
population was H2BGFP-/CD24+/CD29lo cells.    Therefore, CD14 clearly is not an ideal 
marker for isolating the multipotent pregnancy-activated progenitor within the 
CD24+/CD29lo population.  Nevertheless, an imperfect marker is still less cumbersome than 
the requirement for two strains of transgenic mice, and can be used more broadly to test 
changes in the pregnancy progenitor population in studies of other transgenic mice with 
mammary phenotypes.  Therefore, I tested the ability of CD24+/CD29lo/CD14+ MECs to 
form mammary structures in vivo compared to the CD24+/CD29lo/CD14- population, in 
both virgin and pregnant recipients.   
Surprisingly, all transplants produced far more outgrowths than were anticipated 
based on published studies and my multiple previous experiments, resulting in calculated 
MRU frequencies much higher than expected.  CD24+/CD29lo/CD14+ MECs had a 
calculated MRU frequency of 1/460 in virgin recipients and 1/180 in pregnant recipients 
(Figure A-5a, c).  CD24+/CD29lo/CD14- MECs had a calculated MRU frequency of 1/1,300 
in virgins and 1/220 in pregnant mice (Figure A-5b, d).  In order to eliminate any possibility 
of contamination from H2BGFP- populations, mammary outgrowths were sectioned and 
immunostained, and only outgrowths that stained positive for GFP were counted.  The 
recalculated MRU frequency for CD24+/CD29lo/CD14+ cells was 1/1,100 in virgins 
and1/550 in pregnant mice, whereas CD24+/CD29lo/CD14- cells did not give rise to GFP+ 
outgrowths in virgins and had a calculated MRU frequency of 1/880 in pregnant mice.   
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Figure A-5. Limiting Dilution Transplants of CD14 Populations in Virgins and Pregnant Mice. MECs were isolated 
from four week old MMTVrtTA/H2BGFP females and CD24+/CD29lo/CD14+ and CD24+/CD29lo/CD14- 
populations were sorted and transplanted into mice which were left virgin (a, c) or made pregnant (b, d).  Mammary glands 
were counted (upper) and scored for size (lower).   
120 
 
  
Figure A-6. Limiting Dilution Transplants of CD14 Transplants - GFP+ glands only. Data from Figure A-5 was 
filtered to include only mammary glands which demonstrated GFP+ expression.   
121 
 
 
These recalculated repopulation rates are still well above the expected repopulation rates of 
the injected CD24+/CD29lo subpopulations.   
Discussion & Future Directions 
 In the search for a cell surface marker that could isolate the pregnancy-activated 
multipotent progenitor within the H2BGFP+/CD24+/CD29lo population independently of 
MMTVrtTA/H2BGFP transgene activity, twenty-four antibodies were tested by flow 
cytometry.  These antigens were selected from the microarray comparing the 
H2BGFP+/CD24+/CD29lo cells with H2BGFP-/CD24+/CD29lo cells, and from known 
markers of the mammary stem cell hierarchy.  For eighteen of these antibodies, I found no 
difference or minimal differences in staining between H2BGFP+/CD24+/CD29lo and 
H2BGFP-/CD24+/CD29lo populations.  Whether these assays accurately represent the 
expression of these proteins on the cell surface, or whether these antibodies did not function 
in flow cytometry is unknown.  Some of the antibodies (AREG, CD164, Il33, Muc1, PRLR) 
used were not previously tested in flow cytometry, or were tested in non-physiological 
conditions, such as transgenic overexpression of the antigen, that could have resulted in the 
apparent success of a relatively weak antibody.   
 Notably, CD61 did not differentiate between the H2BGFP+ and H2BGFP- 
subpopulations of the CD24+/CD29lo compartment.  On the basis of in vitro  assays, 
CD24+/CD29lo/CD61+ cells have been reported to represent luminal progenitors, whereas 
CD24+/CD29lo/CD61- cells were reported to be a more differentiated cell population.  
Because CD61 expression did not differ significantly between H2BGFP+/CD24+/CD29lo 
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and H2BGFP-/CD24+/CD29lo MECs, H2BGFP+ cells must represent a distinct sub-
division of functional mammary cells within the CD24+/CD29lo compartment.   
 The H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations 
demonstrated different flow cytometry profiles for six of the antibodies tested.  For these 
antibodies, the data suggested that either the H2BGFP+ or H2BGFP- compartments 
contained distinct subpopulations with different expression of the tested cell surface 
markers.  These results were not surprising, as the CD24+/CD29lo subpopulations are 
expected to be mixed, based on quantitative transplantation studies and in vivo assays.  Of the 
candidate cell surface markers displaying differences within the CD24+/CD29lo populations, 
the differences in EpCAM, FGFR2 and Jag1 were deemed too small to be useful for cell 
separation; however, the future development of more effective antibodies against these 
antigens could potentially be used for isolation of the H2BGFP+/CD24+/CD29lo 
populations.  The H2BGFP-/CD24+/CD29lo population was found to contain a Sca-1+ 
subpopulation, which was expected, as Sca-1 is expressed in differentiated MECs [12]; 
however, this confirmation of previously reported data was not useful for separation of the 
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo cells, because the Sca-1+ and 
Sca-1- populations overlapped significantly.  CD49b and CD14 were tested, separately and in 
combination, as possible markers for isolation of H2BGFP+/CD24+/CD29lo MECs; CD14 
was found to be the more effective marker because of its ability to distinguish distinct 
CD14+ and CD14- populations, and was therefore used to isolate CD24+/CD29lo 
subpopulations that were tested for pregnancy-specific activity.   
 The results of the cleared fat pad transplants followed the predicted mammary 
outgrowth pattern only insofar as CD24+/CD29lo/CD14+ cells had a higher repopulation 
rate than CD24+/CD29lo/CD14- cells, and that pregnancy increased the calculated MRU rate 
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of both populations.  However, the mammary repopulation rates for transplants of 
CD24+/CD29lo/CD14+ and CD24+/CD29lo/CD14- cells were very high.  Even when the 
data were filtered to include only GFP+ outgrowths, the mammary repopulation rate 
remained far higher than expected.  Because H2BGFP+/CD24+/CD29lo MECs had a 
calculated MRU frequency of ~1/300 in pregnant recipients (Figures 3-4, 3-8), and because 
approximately 30% of the CD24+/CD29lo/CD14+ cells were H2BGFP+, the expected MRU 
frequency of CD24+/CD29lo/CD14+ MECs was ~1/1,000.  Because the 
CD24+/CD29lo/CD14- population also contained ~20% of the H2BGFP+/CD24+/CD29lo 
cells, it was possible, if unlikely, that the multipotent mammary progenitors were contained 
in the CD14- population.  Yet, neither of these possibilities explains the extremely high rate 
of fat pad repopulation observed in these transplants.  This result is surprising, particularly 
because the CD24+/CD29lo compartment is believed to contain no stem cells and was 
originally reported to have no repopulation activity.  Because my numerous previous 
transplant experiments have agreed with published data concerning mammary repopulation 
rates (Figures 2-11, 3-4, 3-8), I concluded that this anomalous result is not due to problems 
with the mammary fat pad transplants.   
 There are several possible explanations for these unexpected data.  One possibility is 
that some minor change in the enzymatic digestion conditions or cell sorting protocol has 
resulted in the addition of doublets (i.e. stem cells adhering to progenitors or mature 
mammary cells) or other contaminating cells to the population of MECs sorted for 
transplant.  Because the digestive enzymes used in these experiments have changed lots 
repeatedly over the years, with no noticeable change in mammary repopulation rate, and 
because the same cell sorting protocols and FACS machines were used for all experiments in 
this thesis, this explanation is possible, but unlikely.  It is also unlikely that the transplant 
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recipient mice, which were obtained from commercial vendors, had different circulating 
hormone levels or otherwise provided a better in vivo environment for growth of mammary 
structures.   
The most likely explanation for this dramatic increase in mammary repopulation 
ability of the CD24+/CD29lo population is a change in the Matrigel co-injected with 
transplanted MECs.  All MECs transplanted in my experiments were co-injected with 
growth factor reduced Matrigel (see Chapter 2, Materials & Methods).  Matrigel can vary 
widely between lots, and contains growth factors or other molecules able to affect cell 
proliferation and differentiation [105].  Valliant et al. reported that CD24+/CD29lo cells were 
unable to form mammary structures in vivo unless co-injected with Matrigel [36]; therefore, it 
is highly likely that different lots of Matrigel could affect the rate of repopulation in 
CD24+/CD29lo cells.  (The CD24+/CD29+ stem cell compartment was unaffected by 
addition of Matrigel [36].)  Because my in vivo transplantation data was heretofore consistent 
across numerous lots of Matrigel, the  batch used in these latest experiments was probably 
anomalous, containing unusually high levels of mammary growth-promoting components.  
Transplants of CD24+/CD29lo/CD14+ and CD24+/CD29lo/CD14- populations using a 
different lot of Matrigel would probably result in the predicted mammary repopulation rate.   
 The fact that Matrigel can so dramatically affect the in vivo growth ability of 
CD24+/CD29lo cells raises the question of what Matrigel components cause this change.  
Van Keymeulen et al. recently reported that myoepithelial progenitors could give rise to fully 
functional mammary structures when transplanted with a critical concentration of luminal 
cells, and speculated that paracrine signaling between the populations was responsible for 
this phenomenon.  It is plausible that the growth factors responsible for such signaling 
might be contained within certain formulations of Matrigel.  Alternatively, previous studies 
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have demonstrated that extracellular matrix stiffness can affect the differentiation of 
mesenchymal stem cells [138].  It is possible that the mechanical structure provided by 
Matrigel, which polymerizes at body temperature, might result in the activation of different 
proliferation or differentiation programs depending on the stiffness of the Matrigel in which 
the transplanted MECs are embedded.  Positive identification of the factor(s) in Matrigel 
that promotes in vivo mammary growth and development could provide a significant 
contribution to our understanding of mammary development.   
 The identification of CD14 as a likely  marker for the pregnancy-activated 
multipotent mammary progenitor subpopulation within the CD24+/CD29lo compartment is 
interesting.  CD14 is a co-receptor for bacterial lipopolysaccharide and mediates the immune 
response to bacterial infections.  A truncated form of CD14 is secreted into breast milk, 
which has been hypothesized to mediate infant gut-bacterial interactions [139].  CD14 also is 
expressed at high levels in the mammary gland during involution, possibly as a signal to the 
immune system to assist in clearing apoptotic cells [140].  Various groups have identified 
CD14 as a potential marker for alveolar progenitors [32, 33]; for example, 
CD24+/CD29lo/CD14+/c-Kit- MECs can form lactogenic colonies in vitro.  Mice that are 
null for the CD14 gene have no reported mammary phenotype; however, study of MEC 
populations in these mice could provide further details about the mechanisms of mammary 
development [141].   
My data suggests that CD14 is a marker for multipotent, pregnancy-activated 
mammary progenitors, but until the effect of Matrigel on the in vivo assays can be clarified, 
the in vivo role of CD14 populations will remain incompletely understood.  In any event, 
CD14 does not provide complete purification of the H2BGFP+/CD24+/CD29lo population.  
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Future studies could identify the other markers that are required in combination with CD14, 
CD24 and CD29 to isolate these pregnancy-activated progenitors.    
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